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1. Introduction 
1.1. Aging process and its consequences  
 Aging is an undeniable and complicated biological process that is indicated by a general 
time-dependent decline in the physiological and biochemical functions of the main systems 
[1, 2]. Aging is also a remarkable risk factor for the advancement of cardiovascular diseases 
[3] and is associated with a significant decline in neuromuscular function and performance 
[4]. The percentage of elderly people in the world is increasing steadily (Figure 1) [5] due to 
the impressive rise in average life expectancy in the past century [6].  
The rapid increase world’s aging population has led to concerns about the general health of 
elderly [7]. It is estimated that until year 2050, the elderly population will increase from 600 
million as it was in the year 2000 to more than two billion (Figure 2) [8].  Several changes are 
observable along with aging, including a reduced capacity oxygen consumption, an 
impairment in cardiorespiratory adaptation and degradation of the nervous system, and 
decadence in muscle mass which characterized by a reduction in muscle mass and by a 
qualitative and quantitative alteration in muscle fibers [2]. After age 30, a change in body 
composition occurs. However, a reduction of about 0.23 kg muscle mass per year is expected 
from ages of 30 to 60 which accelerates to 2% annually from the age of 60 [9]. Indeed, data 
from the most recent longitudinal aging study suggest that muscle strength decreases at an 
intermittent rate of ~ 3% yearly between the ages of 70–79 years [10]. 
 
Figure 1. Percentage change in the world’s population by age: 2010-2050 [1] 
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Due to increasing longevity and the fact that the elderly have twice as many disabilities and 
four times as many physical limitations as people less than 60 years of age [11], it is 
imperative to understand the aging process and the mechanisms associated with healthy aging 
and conservation of functional independence at the end of life [12].  
 
1.2. Sarcopenia phenomenon as a natural consequence of the aging process  
  
1.2.1. Definition    
 
One of the most well-known features of aging is a change in body composition and decline in 
lean body mass [13]. Age related skeletal muscle wasting, also called sarcopenia, plays a 
significant role in reducing performance [14]. The contribution of lean muscle mass in whole 
body weight is approximately ~50% in young adults, which declines to 25% after age of 75 
years. The reduction of muscle mass is generally counteracted by gains in fat mass. The 
lower extremity muscle groups are more at risk for losing muscle mass, with to 40% 
reduction in cross-sectional area (CSA) of the vastus lateralis between the age of 20 and 80 
years [14]. Although sarcopenia has been widely recognized, however, its mechanisms 
remain poorly known and have not received proper attention until quite recently [13]. In the 
recent decades, research on sarcopenia and muscle wasting have grown considerably    
(Figure 3). The term sarcopenia has been derived from Greek sarx (flesh) and penia (loss), 
Figure 2. Young children and older people as a percentage of global population: 1950-2050 [1] 
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letter by letter meaning deficiency of flesh [15, 16]. It has been suggested that up to 40% of 
muscle mass may be lost between the ages of 20 and 70 years. A reduction in skeletal muscle 
mass can start in the early 35 years of age and may speed up to 6% per decade after 30 year 
of age and 1.4% to 2.5% per year after age 60 [16]. 
 Assessed on 13 January 2015 from www.pubmed.gov 
In parallel, leg strength is declined by 10–15 % per decade until 70 years of age, and then by 
25–40 % per decade [17]. Fast twitch fiber are more affected and their size may be reduced 
by 20-50%, despite the fact that slow twitch fibers are less affected, they may be still have a 
reduction by 1-25% in size. The decrement in total muscle mass is more than loss of muscle 
fiber size because of an extra loss of fibers [18]. For example, a 40–45% reduction in CSA of 
the type II muscle fibers was observed in older males compared to young subjects [19].  
Using the difference definitions of sarcopenia makes it inconceivable to compare studies for 
understanding the pathophysiological processes and developing the targeted therapies [20].  
There are no clear clinical outcome parameter for sarcopenia yet and the evaluation of muscle 
quality based on physical performance and strength is undesirable, because other parameters 
such as the neural controller, cardiovascular fitness and joint function are also involved in 
physical performance and strength. Despite the correlation between the amount of muscle 
mass and muscle strength, it has been demonstrated that muscle mass and muscle strength are 
two different entities and therefore the loss of muscle strength occurring with age can be 
described by the term ‘dynapenia’ [20].  
Figure 3. Number of PubMed entries retrieved after entering the search term “muscle wasting 
OR sarcopenia” 
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In 2009, The International Working Group on Sarcopenia (IWGS) provided an operational 
definition for sarcopenia. This definition includes people with functional decline, movement-
related problems, history of repeated falls, recent inadvertent body weight loss, post 
hospitalization, and chronic conditions (such as type 2 diabetes, chronic heart failure, chronic 
obstructive pulmonary disease, chronic kidney disease, rheumatoid arthritis, and cancer), and 
was more suitable in clinical settings [16]. On the other side, in 2010 the European Working 
Group on Sarcopenia (EWGSOP) developed a new definition for sarcopenia [21]. EWGSOP 
recommendations cover both low muscle mass and low muscle function for assessment of 
sarcopenia in clinical and research tests. EWGSOP offers three levels for sarcopenia 
including: The pre-sarcopenia level is specified by low muscle mass but no change in muscle 
strength or performance. The second level of sarcopenia, is specified by low muscle mass 
along with low muscle performance and the third level, known as severe sarcopenia, is 
characterized by decrease of all of three components, muscle mass, strength, and performance 
[8].  A formula has been used for assessment of sarcopenia as appendicular lean mass (sum of 
lean mass of both arms and legs) divided by height squared. Values higher than two standard 
deviations below the mean of a young reference population were categorized as sarcopenia 
[20]. The first step in the management of sarcopenia is to diagnose the condition. 
Unfortunately, at the moment, there is no standard diagnostic criteria for detection low 
sarcopenia [22]. The most commonly used measurement techniques for muscle mass and 
body composition are Dual-energy X-ray absorptiometry (DXA), magnetic resonance 
imaging (MRI), computed tomography (CT) and electrical impedance myography (EIM) [15, 
22, 23].  
Due to practical problems in evaluating muscle mass, it is not easy to estimate the prevalence 
of sarcopenia. Many different methodologies have been used over the last 20 years, and new 
techniques are still being introduced. On average, it is estimated that 5–13 % of elderly 
people aged 60–70 years are impressed by sarcopenia, and the numbers raise to 11–50 % for 
those aged 80 or above [15]. In line with these data, other sources estimate the prevalence of 
sarcopenia in the range from 13% to 24% in adults over 60 years of age to more than 50% in 
persons aged 80 and older [24]. Current estimates suggest that ~200 million people 
worldwide will be affected by sarcopenia by the year 2050 [25]. Women show a higher 
decrease of muscle mass, especially after menopause. The reduction of muscle mass in aged 
people does not affect arms and legs the same way. Muscle wasting is higher in the lower 
limbs irrespective of the sex of the person. However, when Performance parameters, such as 
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muscle quality, are considered, it can be found a sex-dependent differences. Men undergo a 
greater loss in the upper limbs Compared to women whereas no differences in the decline of 
muscle mass in lower limbs have been observed [26].  
   
1.2.2. Consequences  
 
Sarcopenia is, therefore, a multifactorial consequence of aging and indicative a potent risk 
factor for the development of negative health-related conditions in the elderly [2]. 
Additionally, mobility disturbances resulting from muscle wasting is along with decreased 
quality of life and increased social and health care costs in elderly [27]. Sarcopenia is also 
related to acute and chronic disease states, increased insulin resistance, fatigue, falls, and 
mortality. Of the chronic disease states, sarcopenia has been especially associated with 
rheumatologic conditions, especially rheumatoid arthritis in women [28]. In addition, 
sarcopenia is a main risk factor of falls and disability among the elderly people. Dysfunction 
and physical inability in sarcopenic people are 2 to 3 times more likely [8]. Individuals with 
clinically sensible sarcopenia have 4 times higher risk of disability, three times more risk of 
balance impairment, and 3 times greater risk of falling. Therefore, sarcopenia is the single 
most prevalent etiology to falls and fall-related fractures in elderly people [13]. It has been 
estimated that direct healthcare costs related to sarcopenia in the United States of America in 
2000 were $18.5 billion, which was around 1.5% of total healthcare expenses for that year 
[29]. It is estimated that a 10.5% reduction of the outbreak of sarcopenia could lead to a 
reduction of healthcare expenses by 1.1 billion US dollars per year in the United States [20]. 
 
1.2.3. Etiology of sarcopenia   
 
Although the exact mechanisms involved in sarcopenia is still unclear, however, several 
factors have been proposed to be involved in the onset and progression of sarcopenia (Figure 
4). Sarcopenia arises from several physiopathological factors including, but not limited to: 
sedentary lifestyle [9, 14, 30, 31],  chronic inflammation [13, 17, 30, 32], impaired satellite 
cell function [12, 27, 31, 32], malnutrition [9, 12, 13, 30, 32], declines in neural function [12, 
13, 18, 32, 33], hormonal changes [12, 18, 30, 34], mitochondrial dysfunction [18, 34]. It is 
also probable that certain underlying mechanisms are of greater influence than others when 
considering any specific age group, gender, or association with comorbid states [4]. 
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1.2.3.1. Sedentary life style    
 
Physical activity has been defined as any action generated by the contractive activity of 
skeletal muscles that increments energy expenditure. Physical activity is including of daily 
routines like standing up from a chair and taking stairs, as well as Voluntary movements for 
health benefits such as walking or biking. Inactive persons are characterized by doing only 
basic physical activities such as standing, walking slowly and lifting light objects. Lifestyle 
styles related to nutrition, physical activity, exercise, alcohol consumption, and smoking have 
a Significant influence on the advancement of sarcopenia and the ability to prevent and treat 
the loss of muscle mass and function in old age [9]. 
 
 
Figure 4. Schematic model of main factors involved in the onset and progression of the 
sarcopenia and its consequences 
 
One of the main factor involved in sarcopenia is reduced physical activity among older 
people [35]. It has been suggested that at least some of the increasing prevalence of 
sarcopenia after the age of 65 is due to decrease physical activity and smoking [36]. 
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The connection between lean body mass and degree of physical activity and exercise are 
complex. Reduction in physical activity can alter body composition in some ways. One study 
studied relation between body composition and physical activity in older women over a 10 
years period and found that grater levels of physical activity reduced the advancement of 
sarcopenia. The level of muscle loss is increased even greater when an older person has to 
spending a period of bed rest because of illness [37]. In addition, inactive and smoker persons 
had a greater risk for a reduction in health status compared with active and non-smoker 
people. The net impact of a healthier lifestyle on the process of healthy aging is likely going 
together with a compressed cumulative morbidity [38].  
 
1.2.3.2. Chronic inflammation 
 
An age-related disruption in the intracellular redox balance plays an important role in 
generating a chronic state of low-grade inflammation. Chronic cellular inflammation is 
intended for fundamental mechanism of aging and age-related diseases, and it may consider 
as a link between normal aging and age-related pathological processes [39]. There are several 
lines of evidence suggestting that the inflammation being associated with loss of muscle 
strength and mass with aging [40]. Number of studies have implicated increased levels of two 
pro-inflammatory cytokines, Interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF-α), in 
the development of sarcopenia [41-44]. For example, it was observed a 2.8 fold increase in 
TNF-α expression in skeletal muscle of aged male compared to young male subjects [45].  
An increased expression of TNF-α has also been reported in soleus and vastus lateralis of 
aged rats relative to young rats. Furthermore, it has been found that old animals have 
significantly higher plasma TNF-α levels than younger controls with corresponding 
elevations of IL-6 [45]. Animal studies have shown that the supplementation of IL-6 or TNF-
α increases skeletal muscle breakdown, reduces the rate of protein synthesis, and decreases 
plasma concentrations of insulin-like growth factor 1 (IGF-1). The activation of the age 
related inflammatory process is thought to be the consequent of an up regulation of the 
transcription factor nuclear factor be (NF-кB), an important regulator of the innate immune 
response. This fundamental and increased activity of NF-кB that is associated with aging has 
been suggested to be one of the basic causes of sarcopenia [41].  Furthermore, reactive 
oxygen species (ROS) also seems to act as second messengers for TNF-α in skeletal muscle, 
activating NF-кB either directly or indirectly [39]. TNF-α is also linked to sarcopenia because 
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this pro-inflammatory cytokine is known to be associated with other factors that contribute to 
sarcopenia including protein degradation, ROS accumulation and apoptosis. In addition, 
TNF-α may be induced sarcopenia by promoting insulin resistance, impaired muscle repair, 
and amplifying the pro-inflammatory response by up-regulating IL-6 [45]. Notably, pro-
inflammatory cytokines, in particular TNF-α, are potent stimulators of muscle proteolysis 
through activation of ubiquitin-proteasomal system (UPS). This pathway is thought to be 
responsible for the major part of muscle proteolysis and is stimulated by the repeated 
covalent binding of 76-amino acid ubiquitin monomers to proteins targeted for degradation 
[46]. Furthermore, there is evidence that due to hormone-cytokine receptor cross-talk, pro-
inflammatory cytokines like TNF-α that cause muscle wasting may also operate by 
interfering directly with somatotrophic receptors, including insulin-like growth factor 1 (IGF-
1) [47].  
 
1.2.3.3. Mitochondrial dysfunction 
 
Mitochondria are subcellular self-autonomous organelles primarily responsible for the 
generation of energy and adenosine three phosphate (ATP) synthesis. Besides this, 
mitochondria has a significant role in amino acid and lipid metabolism and regulation of 
apoptosis [48]. There are a number of evidence supporting the hypothesis that mitochondrial 
function and biogenesis appear to be altered in skeletal muscles of older adults [28, 49-51], 
which in turn may contribute to altered skeletal muscle mass and function [28]. Alterations in 
mitochondria have been considered in aging, such as reduced total volume, elevated oxidative 
damage, and decreased oxidative capacity. These alternations may resulted in not only a loss 
of muscle mass and function with age, but other diseases associated with aging such as 
ectopic lipid infiltration, systemic inflammation, and insulin resistance [52]. It is well 
established that the amount of synthesis of mitochondrial, myosin heavy chain (a key 
contractile protein) and mixed muscle protein are decreased with age, along with oxidative 
capacity of skeletal muscle [53]. Muscle biopsy samples have determined that certain 
measures of mitochondrial content decrease with age as measured by electron microscopy, 
mitochondrial deoxyribonucleic acid (mtDNA) copy number, proteomics or the activities of 
key tricarboxylic acid (TCA) cycle enzymes such as citrate synthase [53]. Several hypotheses 
have been proposed to explain the decline in mitochondrial function with aging. These 
theories are included increased ROS production, chronic inflammation and/or mtDNA 
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damage [54]. According to the widely-accepted mitochondrial free radical theory of aging, 
mitochondrial dysfunction arising from oxidative damage to mtDNA is the central 
mechanism driving the aging process [55]. Mitochondria have their own DNA (mtDNA); 
however, its role in mitochondrial protein encoding is only 1% of the approximately 1,000. 
The bulk of the mitochondrial proteins are encoded by nuclear DNA and are transported to 
mitochondria from the cytoplasm [48]. The mtDNA is especially unprotected to oxidative 
damage because of its proximity to the electron transport chain (ETC) (the main cellular 
source of oxidants) and the lack of protective histones. Moreover, because of the density of 
mitochondrial genome (i.e., lack of intrones), each mutation is likely to affect gene integrity 
[27]. A defeat of replication of mtDNA may be the reason of a significant deletion in the 
mitochondrial genome; the shorter genome is replicated faster by inducing the formation of 
dysfunction or completely inactive mitochondria [2]. The relevance of mtDNA damage to 
sarcopenia is evidenced by reduced activity of complex I and IV of the ETC reported in aged 
skeletal muscles of various species. It should be noted that high levels of mtDNA deletions 
and ETC abnormalities in fibers often result in morphological distortions, including 
segmental atrophy, fiber splitting, and breakage [27]. Another important aspect to be 
considered is the motility of mitochondria which continuously undergo fusion (mitofusion) 
and fission (mitofission) events that actively alter their morphology [2]. The role of 
mitofusion and mitofission in aging human skeletal muscle still not fully understood, but are 
believed to be to be key components in regulating mitochondrial quality and function. By 
enhancing mitochondrial protein turnover, fusion and fission help the maintenance of 
mitochondrial and skeletal muscle health by avoiding the accumulation of protein damage 
that can evoke the stimulation of apoptotic and catabolic pathways. In order to remove 
damaged parts of mitochondria by exchanging and dilution, two mitochondrial membranes of 
separate mitochondria connect to each other by mitofusion process, whereas mitofission 
separates high damaged parts of mitochondria for removal by mitochondrial specific 
autophagy [56].  
 
1.2.3.4. Hormonal changes 
  
In humans, several hormonal systems appear a gradual reduction in activity during aging, as 
defined by their bioactive hormone concentrations [44]. Several studies have demonstrated 
age-related endocrine declines such as decreases in testosterone, estrogen, growth hormone 
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(GH) and IGF-1 [22, 40, 57, 58]. In addition to the well-documented decline in these anabolic 
hormones, other endocrine systems (including circulating levels of catecholamines) and 
paracrine/autocrine systems (including local IGF-1 production) may play an important role in 
sarcopenia [44]. These pathways also offer important potential opportunities for interventions 
[28]. We will discuss them in more detail in the following. 
 
1.2.3.4.1. Growth hormone 
 
Several hormones have been suggested for having effects on muscle mass, strength and 
function. Among them, GH has been one of the most studied [59]. GH is a single-chain 
peptide of 191 amino acids. The somatotrophs of the anterior pituitary gland are responsible 
for GH production and secretion. GH secretes in a pulsatory manner with a major boost at the 
onset of slow-wave sleep and less discernible secretory episodes a few hours after meals. GH 
production is controlled by the action of two hypothalamic factors, GH releasing hormone 
(GHRH), which stimulates and somatostatin, which inhibits GH secretion. During fasting, 
GH secretion is increased, whereas excess of glucose and lipids inhibits GH release [60]. The 
functions of GH are mediated through the growth hormone receptor protein (GHR), which 
subsequently activates the Janus kinase 2 (JAK2) signal transducer and activator of 
transcription pathway [44]. The main functions of GH are to increase the synthesis and 
releasing of systemic IGF-1 to stimulate local IGF-1 production in skeletal muscle [34]. IGF-
1 derived from circulation and/or tissue then stimulates amino acid uptake and the synthesis 
of nucleic acids and proteins. In addition, GH reduces lipogenesis and promotes lipolysis 
[61]. However, GH also has a number of IGF-1 independent actions. GH can affects other 
cellular processes in skeletal muscle, which may be important during aging. For example, GH 
acutely regulates muscle mitochondrial function by increasing the transcript levels of several 
key mitochondrial proteins and shifting fuel utilization toward increased fat oxidation [44]. 
The secretion of GH is maximal at puberty accompanied by very high circulating IGF1 
levels, with a gradual decline during adulthood [60]. The circulating (blood-borne) levels of 
GH declines progressively after ~30 years of age at an average rate greater than 1% per 
annum [44]. Indeed, in aged men, daily GH secretion is 5- to 20-fold lower than that in young 
adults [60]. It is therefore not surprising that the age-related decline in GH was believed 
initially to be indirectly responsible for age-related changes in skeletal muscle via IGF-1 [44]. 
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1.2.3.4.2. Insulin and insulin-like growth factors 
 
Several studies have been suggested that IGF-1 is an imperative modulator of muscle mass, 
strength and function, not only during development, but also across the entire life span [34]. 
Much of the anabolic effects of GH is mediated via IGF-1 [19]. Skeletal muscle contains a 
population of heterotetrameric transmembrane receptors that bind insulin, IGF-1 and/or IGF-
II to regulate various stages of myogenesis, including proliferation, differentiation and fusion 
of muscle precursor cell [44]. In addition to the mature IGF-1 produced by the liver, skeletal 
muscle is an important source of this hormone. Studies have demonstrated there are at least 
two different types of IGF-1 which produced by skeletal muscle. They are derived from the 
IGF-1 gene by alternative splicing. One of the splice variants is expressed in response to 
mechanical stress like physical activity and is called ‘mechano growth factor’ or MGF and 
the other is similar to the systemic or liver type (IGF-1Ea) important for providing the mature 
IGF-1 required to up-regulate protein synthesis [44]. There are six forms of insulin-like 
growth factor-binding proteins (IGFBPs) and IGFBP-3, -4, -5 and -6 are found in skeletal 
muscle. Overexpression of any of these IGFBP isoforms suppresses IGF-1 function by 
inhibiting its binding to IGF-1R  [62]. The mammalian target of rapamycin (mTOR) 
signaling pathway is important for translation initiation and is therefore critical for muscle 
protein synthesis. One mechanism that activates mTOR signaling is the IGF-1/PI3k/Akt 
pathway [45]. In general, tissue responsiveness to IGF1 is altered with aging. Aging is 
associated with reductions in IGF1R content and phosphorylation in skeletal muscle [60]. 
Cross-sectional studies have been shown, circulating levels of IGF-1 decrease with age in 
both men and women, as well as in rodents [63]. In the older compared to the young males 
subjects, GHR and IGF-1 messenger RNA (mRNA) were reduced by 45% [19]. In addition, 
muscle production of MGF is decreased in old rats in response to mechanical overload. 
Furthermore, both the density and affinity of the IGF type 1 receptor are reduced in the aged 
muscle [31]. Taken together, aging-related decline in IGF-1/Akt/mTOR signaling seems to 
significantly contribute to sarcopenia. 
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1.2.3.4.3. Testosterone and its precursors 
 
During normal aging, the most notable and well characterized change in hormonal systems is 
the decrease in sex hormone production [64]. There is evidence that sex hormones such as 
testosterone, estrogens, and dehydroepiandrosterones (DHEAS), play an important role in the 
age-related onset of sarcopenia [58]. The available data suggest that low sex hormone 
concentrations are among the key mechanisms for sarcopenia and age-induced reduction in 
muscle strength and power. However, the underlying biological mechanisms by which age-
induced sex hormone deprivation affects muscle mass and function are largely unknown [64]. 
It has been demonstrated that androgens, such as testosterone, regulate muscle mass in 
humans. Testosterone is secreted primarily by testicular Leydig cells in males and ovarian 
thecal cells in females, and directly binds to androgen receptors in skeletal muscle, resulting 
in transformation and dimerization of the receptor, followed by nuclear localization and 
subsequent DNA binding [44]. Sex steroids are found circulating in the bloodstream in three 
forms. The majority (~70 %) is strongly bound to sex hormone-binding globulin, with ~20 % 
bound to albumin and only 2–3 % circulating freely. The free and albumin-bound forms are 
considered biologically available components. Estradiol is produced from testosterone by the 
actions of aromatizing enzyme cytochrome P450 19A1. The effects of estradiol on gene 
expression are delivered through nuclear receptors (ESR1 and ESR2) [64]. Another hormone 
associated with muscle mass loss is DHEA, a pro-hormone that can transform into sex 
steroids, such as androgens and estrogens. DHEA plays important roles in the human body 
including increase in muscle mass, improvements in glucose and insulin levels, decline in fat 
mass and the reduction of breast cancer risk [65]. DHEAS may affect muscle function. In 
fact, skeletal muscle is capable to stimulate IGF-1 by converting DHEA into active androgens 
and estrogens and to stimulate IGF-1 which is important in muscle growth and recovery [58]. 
With aging, free testosterone levels are decreased in men and this decline parallels the 
decrease in muscle mass and strength [65]. Aging is associated with low testosterone which 
may lead to decreased muscle mass and bone strength, and thereby to more fractures and 
complications. Testosterone has proven effects to increase muscle mass and muscle function, 
but along with these benefits, there are also problematic side effects [57]. In males, levels of 
testosterone decrease by 1% per year, and those of bioavailable testosterone by 2% per year 
from age 30. In women, testosterone levels drop rapidly from 20 to 45 years of age [40]. A 
substantial number of older men are hypo gonadal. Hypogonadism has been defined as a total 
testosterone concentration of <9.26 nmol/L (2 SD below the mean for healthy young men). 
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As a result, approximately 20% of men >60 years and 50% men >80 years are categorized as 
hypogonadal [22]. In men, age-related decrease in serum testosterone levels has been linked 
with loss of skeletal muscle mass, strength, and physical performance [66]. However, it 
seems that the influence of sex hormones to maintain muscle mass and strength is greater in 
men than in older women [67]. Circulating levels of DHEA decline with age, especially at 
menopause in women. This decrease in DHEA has been shown to be associated with a 
decline in muscle mass and physical function [65]. It is suggested that the age-related decline 
in estrogen and testosterone are related to increases in levels of the pro-inflammatory 
cytokines IL-6 and TNF-α, which may promote the loss of muscle mass during sarcopenia 
[45]. 
 
1.2.3.4.4. Menopause 
 
Menopause is defined as the permanent cessation of menstruation due to loss of ovarian 
follicular activity and is a sign of the end of a normal female fertility. Menopause is begun by 
a period of menstrual cycle irregularity, known as the menopause transition or peri-
menopause, which usually begins in the mid-40s. The menopause transition is characterized 
by many hormonal changes that lead to a dramatic reduction in the ovarian follicle numbers. 
A remarkable reduction in inhibin B seems to be the first endocrine marker of the menopause 
transition with follicle-stimulating hormone (FSH) levels being marginally raised. Significant 
decline in estrogen and inhibin with marked increases in FSH occur only at the late stage of 
menopause transition. At the time of menopause, FSH levels elevate to 50% of final post-
menopausal concentrations while estrogens levels have reduced to about 50% of the 
premenopausal concentrations [65]. The decreases in estradiol and estrone concentrations 
occur much faster, within a six month period around the menopause. The changes are more 
dramatic in estradiol. Both estradiol and estrone levels continue to decrease further during the 
first three postmenopausal years. The postmenopausal status is characterized by the presence 
of a very low constant systemic estradiol level. This is in contrast to the cyclic estradiol 
production during premenopause. Circulating estrone, synthesized from the adrenal steroids 
in peripheral tissue, becomes the most abundant estrogen in the circulation [64]. There is a 
correlation between menopause due to decreased estrogen levels and sarcopenia in women. A 
reduction of estrogen can be resulted in body composition changes, including a loss of 
muscle mass, but an increase in adipose tissue as well as a redistribution of body fat to the 
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visceral region. It was suggested that estrogen may reduce fat accumulation within skeletal 
muscle and may have a direct connection with lipoprotein lipase (which catalyzes triglyceride 
utilization). Therefore age-associated decline in estrogen levels can be related at least in part 
to increased intramuscular fat in postmenopausal and decreased muscle strength [45]. One 
mechanism by which the loss of estrogen may be contributing towards age-related sarcopenia 
may be due to the increase of pro-inflammatory cytokines, such as TNF-α or IL-6 [24]. 
Furthermore, estrogen is able to effect directly on muscle mass through estrogen beta-
receptors on the skeletal muscle cell membrane. Therefore, it should be a close potential 
mechanistic relation between decrease in estrogen levels and an impaired in protein synthesis 
[40]. Both of menopause and sarcopenia are associated with decline in muscle mass, 
however, menopause lead to a rapid while sarcopenia refers to the loss of muscle mass with 
age. Because the muscle mass is affected by many factors, and these factors related to aging 
and menopause, Therefore It is difficult to determine the relative contribution of menopause 
on the initiation and progression of sarcopenia [65]. 
 
1.2.3.5. Neural degeneration  
Muscle contraction is initiated and sustained through the successive recruitment of motor 
units; a motor unit defined as an alpha-motor neuron and all the muscle fibers it innervates 
[44]. All skeletal muscles are composed of motor units and each motor unit contains a motor 
neuron and muscle fibers. Motor units can be differentiated to two main types based on the 
fiber type present in the motor unit. Slow motor units are generally involved of type I fibers 
while fast motor units mainly composed of type II fibers [65]. One of the main endogenous 
factors of sarcopenia is likely related to the decrease in motor neuron function. It has been 
suggested that decline of muscle innervation play a crucial role in the sarcopenic process 
since innervation is important to the maintenance of muscle mass, as well as strength [2]. 
Fortunately, many fibers are re-innervated by other motor neurons thereby minimizing the 
loss of functional muscle fibers. However, the process is insufficient to fully compensate for 
denervation resulting in atrophy and progressive loss of muscle fibers. Fast motor neurons 
seem to be preferentially affected and over time the denervation/re-innervation process may 
result in loss and atrophy of type II fibers and fiber type grouping of particularly type I fibers 
[5]. Individuals over 65 years of age have a large volumetric decline in areas of the brain that 
are involved in producing voluntary muscle contraction [10]. Indeed, in man, a 25% decrease 
in the number of a-motor neurons occurs with aging [68]. The number of motor units is 
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almost steady until age of 60 years, but after that rapidly declines is occurred at a rate of 3% 
per year, as it would be expected 60% loss of motor units at age of 80 years [33]. However, 
the extent of these motor unit losses appears to vary considerably, and could be influenced by 
the neurotrophic effects of circulating growth factors (e.g. IGF-1) that can promote motor 
neuron survival [44].  
 
1.2.3.6. Malnutrition  
 
As a natural consequence of aging, it has been reported that food intake reduced by ~25% 
between 40 and 70 years of age, leading to an increased risk of having inadequate nutrient 
intakes among older people. The growing number of the existing data shows that nutrition 
can have an important moderating effect on sarcopenia particularly in relation to protein, 
vitamin D and antioxidant nutrients [69]. Malnutrition leads to loss of muscle mass. It has 
been shown that aging is associated with a gradual reduction in food intake, which prepares 
to energy-protein malnutrition. Furthermore the elderly may be due to the use of diet, weight 
loss and cholesterol control, inadvertently reduce protein intake [70]. Inadequate caloric 
intake, also known as anorexia of aging, can lead to the development of a reduction in the 
availability of amino acids and consequently reduction of protein synthesis [46]. 
Furthermore, the anorexia of aging may cause the malnutrition, which is related to 
modulation of different hormones including testosterone, leptin, growth hormone, and IGF-1 
that contribute to muscle wasting [71]. The multiple complex mechanisms and interactions 
leading to reduced food intake with aging include early satiety secondary to decreased 
relaxation of the fundus, increased release of cholecystokinin in response to fat intake, 
increased leptin levels, which may in part be due to increase in fat mass with aging, and the 
effects of neurotransmitters such as opioids and neuropeptides [4]. Recent data indicate that 
lean mass in older adults is significantly and positively associated with dietary protein intake. 
Inadequate protein intake seems to be an important factor for sarcopenia progression in older 
adults [46]. The current recommended dietary allowance (RDA) of protein is 0.8 g/kg/day 
[9].  It has been shown that 15% of those over 60 years eat less than 75% of the RDA [4]. 
Furthermore, based on nitrogen balance studies, it has been recommended that aging 
population needs greater protein (1.14 g/kg/day) relative to the young (0.8 g/kg/day) [9]. One 
of the reasons that older people need more protein than the recommended amount, can be due 
to the phenomenon “anabolic resistance,” a blunted response of muscle protein synthesis 
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(MPS) following taking of dietary protein in the elderly compared to the young. Interestingly, 
this anabolic resistance is associated with decrease in IGF-1 levels in old age. IGF-1 activates 
mTOR which in turn regulates MPS by initiating translation. Thus, disruption in mTOR 
signaling leads to decreased capacity and efficiency of protein synthesis [9]. Nutrients, 
especially free amino acids, are sensed by the mTOR kinase, which then inhibits autophagy 
[72]. Vitamin D has recently received considerable attention as a potential factor involved in 
sarcopenia [69]. It is evident that vitamin D plays an important role in bone and muscle 
metabolism. Several mechanisms have been suggested for the role of vitamin D in muscle 
function [22]. Human skeletal muscle has a receptor for 1, 25-dihydroxyvitamin D. The 
change of muscle fibers as well as muscle differentiation-related genes (Myogenic factor 5 
(Myf5), myogenin, E2A, and so on) occurs independently of calcium metabolism changes in 
vitamin D receptor-deleted mice [73]. Several studies have shown the beneficial effects of 
vitamin D on skeletal muscle and its ability to prevention of muscle damage [9].   
  
1.2.3.7. Satellite cell dysfunction 
   
While the underlying causes of sarcopenia have yet to be elucidated completely, one potential 
mechanism involves the age-related decline in muscle regenerative capacity, possibly as a 
consequence of a decreased number and/or function of quiescent skeletal muscle precursor 
cells (satellite cells) [43]. Myofibers are post-mitotic cells, and their nuclei do not proliferate. 
New myonuclei are provided by a population called satellite cells [74].  Satellite cells are a 
heterogeneous collection of adult muscle stem cells that are normally quiescent. They were 
first identified more than 50 years ago as a unique population of nuclei that were 
“sandwiched” between the sarcolemma and the basement membrane of the muscle fiber. 
While satellite cells might become activated to the changing cellular niche, they do not be 
exposed until a considerable injury or stress (e.g., exercise loading) occurs [32]. In response 
to injury, satellite cells are activated to form myoblasts create new fibers by fusion together. 
In response to an Injury the IGF synthesis increases and stimulates both satellite cell 
proliferation and differentiation into myoblasts [62].  After proliferation, satellite cells will 
fuse together with existing myofibers [75]. Satellite cells represent the endogenous source of 
muscle precursor cells which undergo activation, proliferation and differentiation to form 
‘new’ muscle fibers, a process regulated by the muscle regulatory factors (MRFs) [44] such 
as myogenic differentiation 1 protein (MyoD), MRF4, Myf5, and myogenin. Specifically, 
MyoD and Myf5 are involved in stimulating myoblasts to enter differentiation and join the 
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muscle lineage, whereas MRF4 and myogenin are suggested to mediate terminal 
differentiation of myoblasts [76]. Pax7 regulates Myf5 and MyoD expression levels in 
satellite cells. The satellite cell pool is reproduced by the part of activated satellite cells that 
maintain a high level of Pax7 [32]. It is thus possible that alterations in MRF expression or 
activity may play a role in muscle wasting during aging [5]. The proliferation and fusion of 
the satellite cell is regulated by specific growth factors protein, (mainly IGF-1) but is also 
influenced by hormones such as GH, testosterone, and estrogen [2] and several signaling 
pathways, such as Wnt-ß-Catenin, DeltaL/Jagged1-Notch or Smad2/3- transforming growth 
factor ß (TGF-ß)/Activin/Myostatin [13]. With aging, Notch activation declines due to a fall 
in MAPK activity, thereby reducing satellite cell activation. This process is compounded by 
accumulation of cyclin-dependent kinase due to an elevation in the levels of TGF-ß. It can 
then deactivates satellite cells and suppresses their regenerative function to injury [33]. 
Reductions in Notch signaling is associated with reduced satellite cell proliferation and an 
inability to generate myoblasts in following muscle injury [32]. Wnt signaling is another 
mechanism witch has also been shown to be involved in satellite cell proliferation and 
differentiation in skeletal muscle regeneration [71]. By several studies, it has been 
demonstrated an age-related decrease in satellite cell number in rodents and humans. It has 
been reported that the mean number of satellite cells decreased in type II, but not type I fibers 
of the vastus lateralis muscle of healthy elderly men, which may help to explain the various 
responses of fast type II fibers compared with slow type I fibers with aging [44]. Although 
the mechanisms involved in satellite cell function changes associated with aging is unclear, 
however, the reduced efficiency of anabolic hormones such as IGF1 and testosterone is seems 
to be a key factor. In this regard, recent studies have been demonstrated that a spliced variant 
of IGF1, known as mechano-growth factor (MGF), may also play a critical role in satellite 
cell proliferation [46].  
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1.2.4. Cellular mechanisms and signaling pathways involved in sarcopenia 
 
Approximately 50 percent of total body weight is composed of lean muscle mass in young 
adults, but declines with aging to 25% at 75–80 years of age. The loss of muscle mass is more 
obvious in in the lower limb muscle groups. For example, it has been reported about 40% 
reduction in the CSA of the vastus lateralis between the ages of 20 and 80 years [77]. 
Maintenance of skeletal muscle mass is mainly dependent on the balance between protein 
synthesis and breakdown. An increase in protein breakdown leads to the muscle atrophy, 
whereas an increase in protein synthesis leads to muscle hypertrophy [78]. Numbers of 
cellular mechanisms and signaling pathways are involved in age-related skeletal muscle 
wasting in mammals (Figure 5). These are discussed in more detail in the following section. 
 
 
1.2.4.1. IGF-1/Akt/mTOR 
 
One of the central pathways to muscle size control is the PI3K/Akt pathway, a pathway 
modulated by IGF-1 and insulin. Stimulation of protein synthesis and hypertrophy involves 
these hormones interacting with their respective tyrosine kinase receptors to phosphorylate 
Figure 5. Molecular mechanisms involved in sarcopenia which can be viewed as the result of a 
protein synthesis/degradation imbalance 
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IRS-1 and activate PI3K/Akt signaling that activates mTOR, and in turn, phosphorylates the 
targets 70-kilodalton ribosomal S6 protein kinase (p70S6K) and 4E-binding protein 1 (4E-
BP1) [79]. Compared with wild-type controls, transgenic mice that overexpress IGF-1 under 
the control of muscle-specific promoters has increased muscle mass, CSA, and maximum 
isometric force [80]. The effects of IGF-1 are mediated generally by the type 1 IGF receptor 
(IGFR1), which has tyrosine kinase activity and signals through the PI3K/AKT pathway. 
IGF-1 also binds to the Insulin receptor (IR) but with much lower (about 100-fold lower) 
affinity than to the IGF1R. There are six IGFBPs. Most serum IGF-1 is found in a tripartite 
complex with IGFBP3 and the acid labile subunit (ALS). IGF-IGFBP complexes are able to 
leave the circulation and effect on tissue unless they are bound to the ALS. In serum, they 
increase the circulating half-life and delivery of IGF-1 to tissues. In tissues, IGF function can 
be modulated due to a higher affinity for IGFs than the receptors. Releasing IGFs from 
IGFBPs Can occur by proteolysis of IGFBPs or binding of the IGFBPs to the extracellular 
matrix [74]. Akt/protein kinase B is a ser/thre kinase that has been shown to be a critical 
signaling component for the regulation of cellular metabolism, growth, and survival [81]. The 
Akt family is composed of three members: Akt1, Akt2 and Akt3. These three isoforms share 
over 80 % homology and are expressed in a tissue specific manner, thus the Akt1 and Akt2 
isoforms are predominantly expressed in skeletal muscle, the brain, heart and lungs and Akt3 
is more expressed in the brain and testicles [82]. Akt plays a number of roles that may be 
important in sarcopenia. These roles are included the inhibition of apoptosis and protein 
degradation in skeletal muscle by increasing phosphorylation and inactivation of the pro-
apoptotic protein Bad and forkhead box O (FOXO) transcription factors, respectively [39]. 
The activation of Akt at same time reduced atrophy by phosphorylating FOXO transcription 
factors, preventing translocation to the nucleus where they would otherwise promote the 
transcription of atrophy-related genes muscle RING-finger protein-1 (MuRF1) and muscle 
atrophy F-box (MAFbx), both of which are ubiquitin ligases that degrade proteins [79]. In 
response to activation of Phosphatidylinositol-3-kinases (PI-3K), phospholipid generation 
increase inside the plasma membrane, which in turn recruit and activate AKT kinase, 
resulting in activation of mTOR and p70S6K [62]. The mTOR acts as a main integrator of a 
broad range of signals that regulate protein synthesis and cell growth. Moreover, mTOR 
indirectly inhibits the translation initiation factor elF4E through directly phosphorylation of 
the protein 4E-BPI. Other mTOR role in increased protein synthesis and muscle mass due to 
its impact on decreasing phosphorylation of S6K kinase, leading to the increase of skeletal 
muscle cross-sectional area [82]. Furthermore, Yin Yang 1 (YY1) physically interacts with 
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mammalian target of rapamycin complex 1 (mTORC1) and mediates mTOR-dependent 
regulation of mitochondrial gene expression via an YY1– Peroxisome proliferator-activated 
receptor-γ coactivator 1-α (PGC-1a) complex [72]. An important negative regulatory element 
in this pathway is the protein Tuberous Sclerosis Complex 2 (TSC2). The TSC2 can 
negatively regulates p70S6K activation in response to IGF-1 by downregulating mTOR 
activation. Phosphorylation of TSC2 by AKT on critical residues, leads to reduce its negative 
regulation on mTOR and consequently increase protein translation. This ability of TSC2 to 
regulate translation is linked directly to cellular energy status [62]. Recent studies 
demonstrate an age-related decline in both systemic and locally derived IGF-1, which may be 
responsible, at least in part, for the age-related decrease in skeletal muscle mass and function 
because of decrease activity of the Akt signaling pathway. Numerous of studies have 
indicated cross-talk between ROS, the proinflammatory cytokine TNF-α, and IGF-1 [39]. 
Skeletal muscle biopsies from older male subjects show a reduction in the cross section area 
(CSA) of type II muscle fibers by 40–45%, in parallel with a 45% decreased GHR protein 
and IGF1 mRNA levels, as well as increased TNF-α and suppressor of cytokine signaling-3 
(SOCS-3) mRNA levels, when compared with younger donors. Furthermore, total Akt, but 
not pAkt, proteins levels increased by 2.5-fold, resulting in a 30% decline in the efficiency of 
Akt phosphorylation in older subjects [60]. 
 
1.2.4.2. MAPKs 
 
Mitogen-activated protein kinases (MAPKs) are protein Ser/Thr kinases that induct 
extracellular signals into a broad range of cellular processes. In the eukaryotic cells 
coordination of multiple MAPK pathways regulate several cellular processes such as gene 
expression, cell division, metabolism, motility, survival, apoptosis, and differentiation [83]. 
The MAPK family of proteins is composed of four distinct signaling modules in skeletal 
muscle: 1) extracellular signal-regulated kinase (ERK) 1/2; 2) p38 MAPK; 3) c-Jun N-
terminal kinases (JNK); and 4) ERK5 or big MAPK. These MAPK subunits are activated by 
cytokines, growth factors, and cellular stress [84]. MAPKs are stimulated by phosphorylation 
on regulatory tyrosine and threonine residues by upstream MAP kinase kinases (MKKs), and 
are deactivated by dephosphorylation on by MAPK phosphatases (MKPs). Despite the 
important role of MAPKs in myogenesis, relatively little information have been known about 
the role of the MAPKs in fiber type establishment. One function for ERK1/2 has been 
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indicated in type I fiber expression by increases myosin heavy chain (MHC) type I expression 
via activation of Ras. The ERK1/2 signaling pathway can stimulates several substrates, such 
as p90RSK, leading to the initiation of transcription factors and the ribosomal subunit S6 
[54]. ERK1/2 can also activate kinases associated with protein translation such as Mnk1 and 
its downstream substrate, eIF4E. One study recently found that the higher baseline levels of 
ERK1/2, p90RSK and Mnk1 in aged compared to young muscle, is possibly a compensatory 
mechanism by the skeletal muscle with increasing age, trying to increasing protein synthesis 
[39]. It has also been shown that p38 MAPK actives the MHC type IIx (intermediate) gene 
expression in myoblasts [54]. In this regard, It has been indicated exposing myotubes to 
either TNF-α or Hydrogen peroxide (H2O2) led to activation all the p38, ERK1/2, and JNK 
[39]. Although role of MAPK in the aging process in vertebrates is still not clearly 
understood, however, some studies in drosophila as well as c. elegans have reported a 
contribution for MAPKs for increase of longevity. Whereas the role of p38 MAPK in 
enhancement of longevity is controversial, JNK activity promote longevity by antagonizing 
insulin signaling. Additionally, decreased ERK1/2 activity throughout aging is known to 
promote senescence [54]. 
 
1.2.4.3. FOXOs  
 
FOXOs transcription factors consist a large family of proteins Identified by a protected DNA-
binding domain termed the FOXO [39]. The FOXO family members which play a 
considerable role in skeletal muscle include three isoforms: FOXO1, FOXO3 and FOXO4 
[72]. The FOXO isoforms are predominantly located in the nucleus where they are activated. 
However, when they are phosphorylated, mainly by Akt protein, these FOXO proteins are 
displaced to cytosol, and they are not able to induce the transcription of genes involved in 
muscle atrophy [82]. Thus, when Akt is active, protein breakdown is suppressed, and when 
FOXO is induced, protein synthesis is blocked. The FOXOs activity is regulated by several 
post-translational modifications, such as phosphorylation, acetylation and mono- and 
polyubiquitination. Adding an additional level of complexity, the regulatory consequences of 
these changes appear to be specific for individual FOXO members [72]. Thus the FOXOs 
proteins may very well play a role in the loss of muscle mass or muscle nuclei with aging 
[85]. Recent studies have been provided evidences that FOXO1 suppresses the efficiency of 
anabolic pathways in skeletal muscle via increased expression and reduced phosphorylation 
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of the translational repressor protein 4E-BP1 and impaired signaling via reductions in mTOR 
and Raptor levels. Based on these observations, the possibility can be considered that, in 
mammalian skeletal muscle, FOXO1 may not only stimulates the catabolic processes through 
activation of ubiquitin ligases, but may also inhibits anabolic pathways. FOXO1 may be an 
important therapeutic target for human diseases in which anabolism is impaired [39]. FOXOs 
are among the age related transcription factors which are involved in the redox regulation. 
Increased FOXO1 mRNA has been reported in aged muscle using standard microarray 
analysis, while another study demonstrated increased atrogin-1 mRNA in aged rats [39]. 
Furthermore, It has been found FOXO1 expression in nuclei of aged muscle was higher than 
those of young muscle [85]. It has also been identified that the FOXO-regulated ubiquitin E3-
ligases Atrogin-1/MAFbx and MuRF1 is common in muscle atrophy caused by a range of 
etiologies [86]. In this regard, it has recently been shown that under energy stress situation 
AMPK increased activation of FOXO3 in myofibers, inducing expression of atrogin-1 and 
MuRF1 [72]. In skeletal muscle, FOXO4 is believed to be the most common expressed 
member of the FOXOs [86]. FOXOs activity is also regulated by direct or indirect functions 
of co-factors and by interaction with other transcription factors. An interaction has been 
demonstrated between FOXOs with PGC-1a. Under catabolic conditions similar to the effect 
observed for expression of constitutively active FOXO3 during aging and sarcopenia, 
maintaining high levels of PGC-1a protects muscle mass. 
 
1.2.4.4. TGFβ (Myostatin) 
 
Other factors that have been shown to modulate muscle regeneration belong to the family of 
TGFßs, which are known to suppress myogenic differentiation [43]. Myostatin, a member of 
TGFß superfamily, is one of the main signaling pathway that regulates skeletal muscle 
growth. Myostatin is produced by skeletal muscle and negatively regulates muscle growth 
[72]. It is expressed in both embryonic and adult skeletal muscle, suggesting that myostatin 
acts as a regulator of both prenatal and postnatal myogenesis [87]. Myostatin, similar with 
other family members, after synthesis to a precursor protein then is cleaved by furin proteases 
to produce the active C-terminal dimer [40]. Studies indicate that myostatin regulates cell 
cycle progression and myogenic regulatory factor levels, thereby controlling myoblast 
proliferation and differentiation during developmental myogenesis. In addition, myostatin 
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also influences postnatal muscle growth. In support, it has been reported that myostatin is 
able to regulate myogenesis via the suppression of satellite cell activation in mice [87]. It has 
been demonstrated that adding purified myostatin to differentiated myotubes in culture led to 
an inhabitation of protein synthesis and decreased myotube size. Furthermore, systemically 
administration of myostatin has been shown for inducing muscle atrophy in mice [72]. 
Myostatin is believed to mediate its actions on skeletal muscle via activin type II receptors A 
(ActRIIA) and activin type II receptors B (ActRIIB), with more affinity for ActRIIB [44], 
Binding myostatin to ActRIIB resulted in forming a complex with a second surface type I 
receptor, either activin receptor-like kinase 4 (ALK4) or activin receptor-like kinase 5 
(ALK5), leading to stimulation of the phosphorylation of receptor Smad (Rsmad), and 
Smad2/3 transcription factors in the cytoplasm. Then Smad2/3 modulate nuclear gene 
transcription such as MyoD by translocation from cytosol to nuclear through a TGF-ß-like 
mechanism [29]. The effect of myostatin, which mediated by the transcription factors Smad2 
and Smad3, also interact with IGF1-Akt signaling. Myostatin has been reported to upregulate 
the ubiquitin ligases atrogin1 and MuRF1 via FOXO transcription factors. In this regard, 
myostatin administration has been shown to blocking the IGF1-PI3 K-Akt pathway and 
activation of FOXO1, allowing increased expression of atrogin-1. This connection between 
the two pathways is independent of NFкB [63]. In contrast, Smad2/3 inhibition increase 
muscle hypertrophy partially dependent on mTOR signaling [40]. 
The involvement of myostatin in loss of muscle mass during aging is still debatable. 
Significant increase in myostatin mRNA and protein levels (2- and 1.4 fold respectively) has 
been found in the older males compared to the young subjects [19]. In contrast, there was an 
increase in serum levels of TGF-ß in old humans, but circulating levels of myostatin were not 
different between young and older subjects. It has been indicated that despite any 
recognizable increase in circulating myostatin levels, local intramuscular content of 
myostatin are increased with aging in humans [80].  
In order to examine the contribution of myostatin in age-related sarcopenia, Siriett et al. [87] 
studied muscle mass and regeneration in young and old myostatin-null mice. Their result 
demonstrated there was massive hypertrophy and hyperplasia and an increase in type IIB 
fibers in Young myostatin-null mice subject. Aging was associated with increasing oxidative 
and fiber atrophy in muscle of wild-type. In contrast, there was no fiber type switching and 
also lower atrophy in aged myostatin-null muscle. Aging did not lead to significant effect on 
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satellite cell number, however, satellite cell activation reduced significantly in both wild-type 
and myostatin-null muscles [87]. GH and IGF-1 may have an inhibitory effect on myostatin, 
therefore one potential cause of increased myostatin in aged skeletal muscle is the attrition of 
GH and IGF-1 expression. Myostatin may decreased muscle growth by inhibition satellite 
cell activation, as well as promoting an adipogenic cell fate over myogenicity [45]. 
Proteolysis effect of myostatin can be modulated by at least three interacting proteins, 
namely, GDF-associated serum protein-1 (GASP-1), follistatin, and follistatin-related gene 
(FLRG). It is accepted that the abundance of these endogenous inhibitors of myostatin and/or 
the degree to which they interact with myostatin is independently affected by aging [77]. 
Follistatin is expressed in different tissues and acts as an antagonist of different TGF-ß family 
members [82], Follistatin is expressed in different tissues and acts as an antagonist of 
different TGF-ß family members, which has been thought to be involved in the regulation of 
skeletal muscle mass. Follistatin prevents myostatin from binding to the activin IIb receptor, 
by binding and thereby neutralizing myostatin in the circulation. As a consequence, the 
expression of intramyocellular Smad is prevented, thereby blocking gene transcription. One 
study investigated knockout mice for the gene of follistatin and found excessive loss of 
muscle mass. On the other hand, follistatin-overexpressing mice showed a 327% increase in 
muscle mass compared to the control group. The remarkable increase in muscle mass 
observed in these mice was as a result of an increment in both of muscle hypertrophy (27%) 
and hyperplasia (66%) [82]. Follistatin plays important role in activation of Akt–mTOR 
signaling through decreases activity of Smad3 since constitutively active Smad3 was found to 
suppress follistatin-induced muscle growth and mTOR activation. Other potential reason can 
due to a direct interaction between Smad3 and Akt, as demonstrated in other cell systems, 
may be involved in cross-talk between the myostatin/activin A and IGF1 pathways in skeletal 
muscle [72]. 
 
1.2.4.5. NF-κB 
 
NF-кB transcription factor is a major pleiotropic transcription factor that modulates immune, 
inflammatory, cell survival, and proliferative responses. NF-кB activity seems to directly 
regulate MyoD, which is a myogenic transcription factor, and likely other molecules, such as 
MuRF1, during atrophy. ROS and TNF-α both activate NF-кB [39].   NF-кB is composed of 
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a number of proteins (RelA/p65, cRel, RelB, p50 and p52), known as  NF-кB family 
members that cooperate to form a complex. In most tissues, p65/p50 heterodimers are the 
most frequent and are characterized to be active form of and are involved in most NF-кB 
signaling in skeletal muscle. NF-кB can be kept in an inactive form in the cytosol through the 
binding of an IкB. There are seven isoforms of IкB (IкBα, IкBß, IкBγ, IкBɛ, Bcl-3, p100, 
p105) in mammals with each form possessing the ability to inhibit NF-кB. Upon certain 
stimuli, IкBα is phosphorylated by IкB kinase (IKK) in a step that targets IкBα for 
ubiquitination and subsequent proteolysis, thereby leaving NF-кB unbound. This process 
allows the unbound NF-кB to translocate to the nucleus where it can affect gene expression 
by binding NF-кB-target sequences located in the promoter region of specific genes [88]. 
Although there is little information about the role NF-кB in the onset and progression 
sarcopenia, however, several studies have found a significant causal role for NF-кB 
activation in muscle atrophy [89]. One study has reported that the levels of NF-кB was four 
times higher in the muscles of elderly people compared with their young counterparts.; this 
increased concentration is associated with anabolic signaling deficiency observed in age 
related muscle wasting [39].  Mice transgenic for an active form of IKKß exhibit a muscle 
wasting phenotype. Indeed, inhibition of NF-кB activity in macrophages was associated with 
reduced muscle degeneration, while systemic treatment with an IKK inhibitor reduced 
pathologies associated with muscular dystrophy  [89]. Aging also affected TNF-α signaling to 
NF-кB. Intermediary proteins (IKKβ, IкBα, and p65), which are responsible for the 
transmission of the TNF-α activation of NF-кB, increased with age in the soleus muscle [39]. 
 
1.2.4.6. Apoptosis  
 
Recent studies also suggest that apoptosis might be another mechanism involved in 
sarcopenia [43]. Apoptosis is an important process for cellular function which occurs in 
multicellular organisms and plays Considerable role in normal development and for 
maintaining tissue homeostasis [90]. Apoptosis is a programmed cell death process that 
occurs through a series of coordinated events, resulting in cellular self-destruction without 
inflammation or damage to other cell components [91]. It is hypothesized that the 
acceleration of apoptosis in the aging muscle may represent a converging mechanism through 
which muscle atrophy and physical function decline ensue. Indeed, it has been indicated that 
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there is a positive correlation between the loss of muscle mass and strength and the rate of 
increase in apoptosis associated with aging. Apoptosis is initiated by the induction of signals 
of cell death, which are generated due to unbalance in the regulation of free calcium and 
alteration in the composition of some protein families. After that, activation of cell surface 
receptors or mitochondrial pathways, resulted in triggering cytoplasmic and nuclear events 
that lead to cell death [90]. Broadly, the apoptotic machinery comprises regulatory proteins, 
endonucleases, protease inhibitors and proteolytic enzymes, known as initiator cysteine-
aspartic proteases (caspases). Upon cell death stimulus, caspases initiators (i.e. caspase-8, -9 
and -12) are engaged, leading to the activation of effector caspases (i.e. caspase-3, -6 and -7), 
which are responsible for cellular degradation and DNA fragmentation [91]. Caspases are the 
major enzymes involved in the beginning and the development of apoptosis. They are 
considered for proteolytic cleavage of a wide range of cell targets, although they do not alone 
initiate that process [90]. Two main pathways involved in caspase activation are distinct 
based on the extrinsic or intrinsic origin of the death-inducing stimulus. In The extrinsic 
pathway, caspase is activated through the interaction of cell surface death receptors (e.g. 
tumor necrosis factor receptor (TNF-R)) with their ligands (e.g. TNF-α) [91]. While, intrinsic 
pathways of caspase activation include those triggered by the ER and the mitochondrion. 
Under stress conditions, such as calcium dyshomeostasis, the ER-specific procaspase-12 can 
be activated by m-calpain, leading to caspase-3 activation [31]. Although apoptosis may 
occur via several mechanisms but it has been shown recently that mitochondria plays 
considerable contribution in the regulation of apoptosis. Furthermore it is thought that 
internal cellular stimuli, such as high levels of calcium or reactive oxygen intermediates, may 
trigger apoptosis by the Cytochrome C (Cyto C)-dependent pathway [92]. Upon stimulation, 
mitochondria release Cyto C into the cytosol which then complexes with apoptotic protease 
activating factor-1 (Apaf-1), ATP and caspase-9 forming the apoptosome. The apoptosome 
then activates caspase-9, which in turn cleaves and activates caspase-3, the final executor of 
the apoptotic process [30].  The mitochondria can initiates apoptosis independent of caspase 
activation via the release of Apoptosis-inducing factor (AIF) and endonuclease G (EndoG), 
both of which can directly execute DNA fragmentation [91]. Since the AIF is located in the 
mitochondrial intermembrane space, it plays an important role in mitochondrial function, 
especially for the proper functioning of complex I. AIF acts as a NADH-oxidase activity. 
After being released from the mitochondria into the cytoplasm, it is then transported into the 
nucleus where it binds to DNA to induce chromatin condensation. AIF can also together with 
cyclophilin A constitute an active DNase responsible for fairly large DNA fragmentation. In 
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response to apoptotic stimulations, AIF along with Cyto C release from mitochondria and 
activate the caspase cascade. However, AIF is thought to be able for inducing apoptosis 
independently of caspases. In addition to AIF, under apoptotic conditions EndoG which is a 
mitochondrion-specific nuclease and necessary for normal cell proliferation, releases from 
the mitochondria and enters the nucleus, where it participates in oligonucleosomal DNA 
fragmentation [93]. Since the AIF is located in the mitochondrial intermembrane space, it 
plays an important role in mitochondrial function, especially for the proper functioning of 
complex I. AIF acts as a NADH-oxidase activity. After being released from the mitochondria 
into the cytoplasm, it is then transported into the nucleus where it binds to DNA to induce 
chromatin condensation. AIF can also together with cyclophilin A constitute an active DNase 
responsible for fairly large DNA fragmentation. In response to apoptotic stimulations, AIF 
along with Cyto C release from mitochondria and activate the caspase cascade. However, 
AIF is thought to be able for inducing apoptosis independently of caspases. In addition to 
AIF, under apoptotic conditions EndoG which is a mitochondrion-specific nuclease and 
necessary for normal cell proliferation, releases from the mitochondria and enters the nucleus, 
where it participates in oligonucleosomal DNA fragmentation [31]. Translocation of Bcl-2-
associated X protein (Bax) to the mitochondria in response to apoptotic stimulations, Leads to 
formation of a pore on the outer mitochondria membrane (OMM), subsequently triggering 
apoptotic factors stored in the intermembrane compartment into the cytoplasm. In this 
process the pro-apoptotic factors Bid and/or Bim are involved in activation of Bax and/or 
Bak, possibly through neutralizing B-cell lymphoma-2 (Bcl-2) and Bcl-XL activity. In 
addition, the mitochondrial permeability transition pore (mPTP) opening can also cause 
mitochondrial outer membrane permeabilization (MOMP). The mPTP is a protein structure 
that is composed of three main considered units: a voltage-dependent anion channel (VDAC) 
in the OMM, the adenine nucleotide translocase (ANT) located in the inner mitochondrial 
membrane (IMM), and cyclophilin D (CyPD) in the matrix. Formation of the mPTP requires 
interaction between ANT and VDAC with CyPD associated with the IMM. Opening of the 
mPTP permits free diffusion of low-molecular weight solutes across the IMM. This results in 
a mitochondrial permeability transition (MPT), conditions that lead to uncoupling of 
oxidative phosphorylation and reduced ATP production [93]. Several stimuli, including 
calcium, oxidative stress, and TNF-α can trigger apoptotic signaling in aged skeletal muscle. 
Recently age-related sarcopenia and muscle fatigability have been suggested to be associated 
with increased ROS production, enhanced mitochondrial apoptotic susceptibility, and 
reduced transcriptional drive for mitochondrial biogenesis [39]. In addition, an age related, 
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increased cytosolic Ca2+ levels may have contributed to the activation of the endoplasmic 
reticulum-mediated apoptotic pathway [39]. An increased expression of pro-apoptotic 
proteins and caspases and DNA fragmentation have been found, with a concomitant decrease 
in expression of anti-apoptotic proteins in aged skeletal muscle [45]. Results from human and 
animal studies have found that caspase-independent pathway is upregulated with age [52]. In 
this regard, higher levels of the pro-apoptotic protein AIF, with an associated decrease in the 
apoptotic repressor with a caspase recruitment domain (ARC) has been reported in aged (26 
mo) rat gastrocnemius relative to adult (12 mo)  [45]. Age related increase in the proportion 
of apoptotic cells was found generally more in type II fibers in humans [52]. A different age-
related pattern of Bcl-2 and Bax expression has also been indicated in rats based on the 
muscle type. In this regard, Bax content was elevated at old age in the extensor digitorum 
longus (EDL), whereas no changes were found in the soleus. In contrast, an increased 
expression of Bcl-2 was observed in both muscles at advanced age [93]. In connection with 
this, a higher muscle cell apoptotic index was found in the plantaris muscles (9.9-fold) as 
opposed to the soleus muscles (3.2-fold) in rats following hind limb suspension in aged rats 
compared with ambulatory control rats. This finding proposes the concept that incidence of 
muscle cell apoptosis could vary depending on muscle types or even between species [94]. 
 
1.3. Therapeutic strategies 
 
Pathology of sarcopenia is multifactorial and there are no effective cure until now [42, 71]. 
However, due to this multifactorial cause, previous studies have examined alone or in a 
combination of the different therapeutic strategies, including nutritional and pharmacological 
intervention [94-97], caloric restriction (CR) [52, 54, 98], exercise training [76, 99-103] and 
hormone therapy [59, 61, 74, 104]. Here we discuss each in more detail. 
 
1.3.1. Nutritional and pharmacological intervention 
 
The current RDA for protein is 0.8 g/kg/day, but almost 40% of people >70 years do not 
consume sufficient amounts of dietary protein which leads to a reduction in lean body mass 
and increased functional impairment [22]. Thus, nutritional interventions may be useful and 
potential strategy for the prevention and treatment of sarcopenia due to the easy applicability 
37 
 
and safety [70]. It has been indicated that anabolic nutrients increase the phosphorylation of 
mTOR-associated signaling proteins in human muscle in association with an increase in 
protein synthesis through both enhanced translation initiation and translation elongation 
signaling [39]. 
Numerous studies have examined the effect of protein and amino acid intervention on MPS in 
the elderly [105-108]. In this regards, Volpi et al. [107] reported that essential amino acid 
(EAA) are mainly responsible for the stimulation of muscle protein anabolism in the elderly. 
They compared the muscle protein metabolism response of healthy elderly to oral 
supplementation of either 18 g EAA or 40 g balanced amino acids in small boluses every 10 
min for 3 h. Their result showed that phenylalanine net balance, a reflection of muscle protein 
balance, increased from the basal state, with no differences between groups, due to an 
increase in MPS and no change in breakdown [107]. In another study, Katsanos et al. [108] 
studied the effects of enriching an EAA mixture with leucine on muscle protein metabolism 
in elderly and young individuals. EAAs were including of whey protein [26% leucine (26% 
Leu)] or were enriched with leucine [41% leucine (41% Leu)]. No significant increase was 
observed in fractional synthetic rate in the elderly following ingestion of 26% Leu EAA, but 
increased following administration of 41% Leu EAA. However, the mean response of muscle 
phenylalanine net balance was promoted in all groups, with the exception of the 26% Leu 
elderly group. They then concluded that increasing the proportion of leucine in a mixture of 
EAA can reverse an attenuated response of MPS in elderly [108]. One possibly underlying 
mechanisms of leucine's effects, similar to those of IGF-1 treatment, can be due to its effect 
on phosphorylation of mTOR, p70S6K and 4EBP-1 [109]. 
It has been suggested that a regime of combination of antioxidants supplementation alone or 
associated with a diet may possibly increase antioxidant defenses, lower muscle oxidative 
damage, and improve muscle protein balance during senescence [2]. Sinha-Hikim et al. [94] 
investigated the effect of administration of a cystine-based antioxidant (F1) on age-specific 
changes in skeletal muscles. Their result showed that 6 months supplementation increased 
markers of oxidative stress, inflammation, and muscle cell apoptosis and decreased muscle 
weight in old mice compared with young mice (5 months old). They then found F1 
administration significantly prevented these age-related changes including inactivation of 
AMPK, increased lipogenesis, activation of c-Jun NH2-terminal kinase, and decreased 
expression of Delta 1, pAkt, and proliferating cell nuclear antigen in aged skeletal muscle. 
These data indicate the beneficial effects of F1 to reduced age associated loss of muscle mass 
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[94]. Positive effects of vitamin D supplementation were also shown, increasing muscle 
strength and performance and reducing the risk of falling in elderly with low vitamin D levels 
[40]. Bischoff et al. [110] have reported that supplemental vitamin D in a dose of 700-1000 
IU a day resulted in a 19% reduced risk of falling among older individuals [110]. 
Furthermore, 2–12 months administration of 800 IU of vitamin D to individuals aged 65 
years and older, markedly enhanced lower extremity strength or function by 4–11 % after of 
treatment [111]. 
Aside from the effect of natural nutrients supplementation, some studies investigated effects 
of pharmacological strategies for age related muscle wasting. In this regards, 
pharmacological inhibition of myostatin may have potential therapeutic benefits in the 
treatment of sarcopenia [22]. LeBrasseur et al. [112] investigated effects of myostatin 
blocking by anti-human myostatin antibody (PF-354) relative to a vehicle control, on 
performance and metabolic measures in 24-month-old mice. At the end of study, PF-354–
treated mice showed significantly greater muscle weights and more than 30% declines in 
muscle fatigue. PF-354 was associated with decreased Smad3 phosphorylation and increased 
PGC-1a expression and decreased MuRF-1 [112]. In another study, Murphy et al. [113] 
found that PF-354 reduced the age related decline in muscle mass and function of mice by 
reducing apoptosis. In fact, there result demonstrated that PF-354 prevented the age-related 
decline in body mass and increased muscle mass. PF-354 also increased fiber CSA by 12% 
and enhanced maximum in situ force of tibialis anterior muscles by 35%. Myostatin 
inhibition by PF-354 increased the proportion of type IIa fibers by 114% and enhanced 
activity of oxidative enzymes (SDH) by 39%. PF-354 significantly reduced markers of 
apoptosis in TA muscle cross-sections and reduced caspase3 mRNA [113]. These data 
suggest a therapeutic potential of the pharmacological myostatin inhibition for sarcopenia. 
Other pharmacological components such as Angiotensin-converting enzyme inhibitors and 
losartan (an angiotensin II receptor antagonist) has been candied and studied against 
sarcopenia [22, 26, 114]. However, further studies are needed to determine their contribution 
to the prevention and treatment of sarcopenia. 
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1.3.2. Caloric restriction (CR)   
 
One of the most powerful anti-aging intervention is CR without malnutrition [27], which 
exerts this effect in multiple ways [54]. CR is generally regarded as consuming 20–40% 
fewer calories than normal [52]. CR intervention positively modulates both primary aging 
(natural age-related deterioration) and secondary aging (accelerated aging due to disease and 
negative lifestyle behaviors) [52]. A number of studies have investigated the effects of CR on 
sarcopenia [115-118]. Bua et al. [115] studied the role of CR (40% restriction without 
nutrition deficiencies) in electron transport system (ETS) enzymatic abnormalities in two 
quadriceps muscles (vastus lateralis and rectus femoris) from ad libitum fed (5, 18, and 36 
months) and calorie-restricted rats (36 months). CR reduced the abundance of ETS abnormal 
fibers in vastus lateralis muscles of the 36-month-old calorie-restricted rats. However, CR did 
not prevent fiber atrophy in ETS abnormal regions. Their result suggest that CR leads in the 
producing of less ETS abnormalities, thus affecting/inhibiting a process that ultimately results 
in fiber loss [115]. CR has been indicated to decreases markers of apoptosis in aging rat 
skeletal muscle [98]. In this regard, Dirks et al. [116] investigated main proteins involved in 
apoptotic regulatation in the gastrocnemius muscle of 12 and 26 month old ad libitum fed and 
26 month old calorie-restricted male Fischer-344 rats. They found that CR significantly 
reduced age-elevated levels of pro- and cleaved caspase-3, apoptosis-inducing factor and 
expression of procaspase-12 compared with their age-matched cohorts. Also increased 
mitochondrial levels of the ARC, which inhibits    Cyto C release, were lower in calorie-
restricted rats, can indicate a translocation of this protein to attenuate oxidative stress. They 
then concluded that CR is able to reduce the potential for sarcopenia by altering several key 
apoptotic proteins toward cellular survival in aged skeletal muscle [116]. Furthermore, 32 
months of CR retarded muscle mass loss in 36 months old rats compared with age match 
controls. However, CR did not prevent age related muscle mass lose while 36 months old 
compared with 21 months old rat in CR groups [117]. CR has been shown to decreases 
oxidant production during aging probably due to an anti-inflammatory effect. This later can 
happen by decreased MAPK activity and enhanced deacetylasion of SIRT1. It has been 
hypothesized that SIRT1 deacetylates, and therefore decreases activity of MKP-1, leading to 
increased PGC-1a function, thus, preventing myofiber dysfunction [54]. Nevertheless, 
regardless of the benefits of CR on sarcopenia one important problem, which should be taken 
into consideration, is the exact time frame for starting CR. When started too early in life, it 
may cause developmental problems and if started too late benefits may not be achieved [71]. 
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1.3.3. Exercise training 
 
It is well accepted that less physically activity in older adult is associated with reduced 
skeletal muscle mass and increased prevalence of disability [4]. A sedentary lifestyle results 
in reduced activity levels and loss of muscle mass and strength [95]. One of the effective 
stimuli for the regulation of multiple metabolic and transcriptional processes in skeletal 
muscle is physical exercise [81]. Exercise is generally categorized to: endurance training, 
which is characterized by low resistance work of longer duration, and resistance training, 
which is characterized by more powerful movements of shorter duration [119]. Both types, 
such as resistance and endurance exercise interventions have been found to be effective in 
preventing and postponing age-associated issues that cause sarcopenia [14]. However, the 
mechanism(s) by which exercise protects skeletal muscle against sarcopenia remain poorly 
understood; it can be, at least in part, due to decreasing intramuscular adipose tissue, pro-
inflammatory cytokine levels, oxidative stress and DNA fragmentation as well as the 
delay/prevention of telomere shortening and increased sex hormone levels, protein synthesis 
and growth factors [45].  
 
1.3.3.1. Resistance training  
 
Resistance exercise training (RT) is an effective intervention for preventing and treating 
sarcopenia due to its ability to stimulate and promote net muscle protein anabolism, resulting 
in specific metabolic and morphological adaptations in skeletal muscle tissue and also in 
positive effects on metabolic, cardiovascular, and reproductive systems [14, 80, 120]. 
Considerable numbers of investigations have examined skeletal muscle responses to both 
acute and chronic RT in the elderly [51, 76, 78, 99, 100, 119]. However, the results of 
previous studies are conflicting regarding the acute effect of RT. In this regard, Fry et al. [78]  
measured intracellular signaling and MPS following an acute bout of RT in young and older 
subjects. At baseline and at 3, 6 and 24 hours after RT, muscle biopsy was taken from the 
vastus lateralis. No changes have been seen in phosphorylation for several key signaling 
proteins, mTOR, S6K1, 4E-BP1 and ERK1/2 after exercise in older group. An increased 
MPS after exercise from baseline has been found only in the younger group [78]. On the 
other hand, Ruae et al. [76] Investigated mRNA expression of several key skeletal muscle 
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myogenic controllers at rest and 4 hours after a single bout of RT in young and old women. 
Subjects performed 3 sets of 10 repetitions of bilateral knee extensions at 70% of one 
repetition maximum. RT led to upregulation of MyoD (2.0-fold) and MRF4 (1.4-fold) and 
downregulation of myostatin (2.2-fold) [76]. Following a series of investigations, Ruae et al. 
[100] Studied acute bout of RT on mRNA expression of ubiquitin proteasome-related genes 
involved in muscle atrophy in very old women. The RT protocol consisted of three sets of 10 
knee extensions at 70% of one-repetition maximum. Muscle biopsies were taken from the 
vastus lateralis before and 4 hours after RT. The result demonstrated an induction of atrogin-
1 and MuRF-1 gene expression in response to RT. These data suggest that in response to RT 
the regulation of ubiquitin proteasome-related genes involved in muscle atrophy are altered in 
very old women (> 80 years) [100] .  
In contrast to acute RT, Melov et al. [51] Compared gene expression profiling and a subset of 
these genes were related to muscle strength in healthy older and younger adult men and 
women before and after a six-month RT program. In response to RT, strength improved 
significantly in older adults. Following RT, the transcriptional signature of aging was 
significantly reversed back towards younger levels for most genes. The authors then 
concluded that mitochondrial impairment and muscle weakness are favorably regulate altered 
at the phenotypic and transcriptome level, following six months of RT [51]. In support of the 
effects of RT on age related changes in mitochondrial function, Luo et al. [99] investigated 
the signaling pathways that regulate autophagy and apoptosis in the gastrocnemius muscles of 
18–20 month old rats in response to 9 weeks of RT. Their finding demonstrated that RT 
prevented the loss of muscle mass by reduced Microtubule-associated protein 1A/1B-light 
chain 3 (LC3)-II/LC3-I ratio, reduced p62 protein levels, and increased levels of autophagy 
regulatory proteins, including Beclin 1, Autophagy-related protein 5/12 (Atg5/12), Atg7, and 
the lysosomal enzyme cathepsin L. These improvements in autophagy signaling were 
associated with an upregulation of total AMPK, phosphorylated AMPK, and FOXO3a 
expressions. Their results also showed that RT inhibited apoptosis by reduced Cyto C level in 
the cytosol, and inhibited cleaved caspase 3 production. They also found that RT upregulated 
the expression of IGF-1 and its receptors, but downregulated the phosphorylation of Akt and 
mTOR. These results suggest an anti-apoptotic role for chronic resistance exercise most 
likely by the inhibitory effects on mitochondria-mediated apoptosis in aged skeletal muscle 
[99].  
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The exact mechanism by which RT stimulates protein synthesis and reduces sarcopenic 
conditions in aged skeletal muscle is not yet fully understood. However, it is well known that 
Akt/mTOR signaling and Akt/FOXO3a signaling are both major regulators of skeletal muscle 
hypotrophy and atrophy. It has been speculated that in response to RT, IGF-1 and its 
receptors, as well as the Akt/mTOR and Akt/FOXO3a signaling pathways may be modulated 
[99]. In fact, in response to RT, IGFI/MGF activate PI3K, which leads to membrane 
translocation and subsequent phosphorylation of Akt by PDKI and PDKII. Once activated, 
Akt phosphorylates mTOR and GSK3ß, which play a mediator role in protein synthesis, 
transcriptional and proliferative processes related to hypertrophic response, as well as the 
control of protein degradation [82]. Other mechanisms that are involved in the synthesis of 
muscle protein are the MAPK signaling pathways. It has been shown that in response to RT, 
phosphorylation of ERK1/2 MAPK is increased and mTOR is activated [9]. mTOR activation 
by the ERK pathway may be through the phosphorylation of TSC2 [82]. It is important to 
consider that the effects of RT are dependent on the mode of exercise, including intensity, 
duration and frequency and also on the tissue types [99]. 
 
1.3.3.2. Endurance training 
 
In addition to resistance exercise, aerobic endurance training (ET) also have been shown for 
potential role in the integrity and health of the aged skeletal muscle [121]. One of the serious 
consequence of aging is a progressive deterioration in aerobic exercise capacity due to 
reduced quantity or quality of skeletal muscle mitochondria [122], as well as decline in 
enzyme activities and protein content [53]. It is well known that ET not only improve 
maximal oxygen consumption (VO2max), mitochondrial density and activity, insulin 
sensitivity and energy expenditure [70], but can also reduce intramuscular fat and improve 
muscle functionality in young and older individuals [9]. An increase in the CSA of muscle 
fibers following ET, supports the notion that ET can contribute to improvement of muscle 
quality [22]. Numerous studies have investigated the effects of acute [81, 123-125] and 
chronic [50, 56, 61, 96, 98, 102, 103, 121, 126-132] ET on age related skeletal muscle 
adaptation in both humans and rodents.  
In order to investigation of acute effect on skeletal muscle mitochondria in older subject, Bori 
et al. [123] Studied a single bout of ET on mRNA levels of genes involved in mitochondrial 
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biogenesis. They were interested in comparing old sedentary and old physically active 
individuals in response to acute ET. Compared to old sedentary control, ET resulted in an 
increased expressions mRNA levels of SIRT1 and AMPK subunit A2, but no change in the 
levels of PGC-1a, AMPK subunit B2, transcription factor A, mitochondrial (Tfam), 
Polynucleotide Phosphorylate (PNPase), Mitochondrial uncoupling protein 3 (UCP3), Lon 
protease, SIRT3. Training also reduced expression of Nrf1, mitochondrial fission protein 1 
(Fis1) and mitochondrial fusion 1 (Mfn1) mRNA levels in old sedentary acute ET. an acute 
exercise bout Led to an significant increase in AMPK subunit A2 and PNPase expressions, 
maintained levels of SIRT1, PGC-1a, AMPK subunit B2, Tfam, Mfn1, UCP3, Lon protease 
and SIRT3, but decreased Nrf1 and Fis1 expression mRNA expression levels in old 
physically active subjects compared to control values [123]. These findings suggest that level 
of fitness may affect mitochondria adaption following acute ET. In contrast to acute ET, 
chronic ET appears to have considerably greater effects. Konopka at al. [56] examined the 
influence of 12 weeks of progressive ET on a cycle ergometer on markers of mitochondrial 
content in old women. Compared to basal levels, ET significantly increased PGC-1a protein 
content and levels of Citrate synthases (CS), ß-hydroxylacyl Co A dehydrogenase (ßHAD), 
succinate dehydrogenase (SDH) and cytochrome c oxidase (Cox) 4. In addition mitofusion or 
mitofission proteins Mfn1, Mfn2 and FIS1 protein contents were greater after ET [56]. In 
accordance with the previous results, Bo et al. [121] Found 12 weeks of ET stimulates 
mitochondrial biogenesis and network and also improves the efficiency of mitochondrial 
energy transfer in old rats. ET also increased Cox 4 content in trained compared with control 
old rats. Furthermore, Dynamin-related protein 1 (Drp1) protein, but not Mfn1, significantly 
increased after ET in the old training group. In addition, in response to training, ATP 
synthase activity -as an indication of mitochondrial energy production- increased when 
compared to the control group [121]. Upregulation of PGC-1a signaling is probably one of 
the main mediators in aged skeletal muscle mitochondrial adaptation to ET [29]. Findings 
from a study conducted by Kang et al. [131] Demonstrated that 12 weeks of ET increased 
PGC-1a content by 2.3 fold in trained compared to control old rats. This increased PGC-1a 
content was correlated with a significant increase in Tfam, Cyto C and mtDNA contents after 
ET in old rats. In response to ET, there was an increase in upstream signaling, involving 
PGC-1a activity including AMPK, p38MAPK, SIRT1 and p- cAMP response element-
binding protein (CREB) in the old trained vs. old control rats. These data indicate that aging-
associated decline in mitochondrial protein synthesis in skeletal muscle can be attenuated 
following chronic ET [131]. In this regards, another study, conducted by Broskey et al. [50], 
44 
 
investigated the effect of 4-month of ET intervention on proteins involved in mitochondrial 
biogenesis in sedentary older adults. In response to ET the levels of complexes III, IV, and V 
were significantly increased. Furthermore, a significant correlation was observed to the 
increase in Tfam expression levels and increase in PGC1a expression levels after the 4 
months of exercise intervention. However, there were no change in Nrf1 and Nrf2 expression 
levels in responses to ET in older sedentary subjects [50]. 
One another important mechanism by which ET supports aged skeletal muscle may be due to 
its role in inhibition apoptosis process [39, 45, 133]. In this regards, Song et al. [98] reported 
that anti-apoptotic Bcl-2 increased, while significant reduction in DNA fragmentation, 
cleaved caspase-3, Bax, and Bax/Bcl-2 ratio were observed in the white gastrocnemius and 
soleus muscles of old rats in response to 12 weeks of ET. Furthermore, age-related decrease 
in upstream anti-apoptotic NF-B activity was reversed following ET [98]. Recently Marzetti 
et al [61] confirmed the hypothesis that age-associated apoptosis occurs less in type I muscle 
fibers, such as the soleus muscle, than type II fibers and therefore less likely to be affected by 
short-term ET. Their result showed, that in contrast to EDL, there was no significant changes 
in TNF-R1 expression, cleaved caspase-8 and -3 content, and apoptotic DNA fragmentation 
in soleus muscle of young and old groups and also in response to ET intervention [61].  
A potential role for ET to increase the circulating levels of IGF-1 has also been suggested 
[134]. In this regard, Poehlman et al. [129] reported that 8 weeks of ET significantly 
increased fasting levels of IGF-1; more markedly in older men than women. There was also a 
significant correlation between changes in VO2max and IGF-1 in men, but not in women 
[129]. In addition, a study conducted by Manetta et al. [125] showed that basal levels of GH, 
IGF-1, and IGFBP-1 were higher in trained middle-aged men when compared with sedentary 
control. Furthermore, their data indicated that acute ET in middle-aged men increased the 
activity of the GH/IGF-1 system [125]. In support of this notion that ET can active anabolic 
factors, Hansen et al. [124] found that plasma follistatin increased by 7-fold following 3 h of 
bicycling exercise, but only increased by 2-fold after one-legged knee extensor exercise. 
These data suggest that increase in plasma follistatin after ET seems to be dependent on 
several factors, including the intensity and duration of exercise and also the muscle mass 
recruited during the exercise bout [124]. In accordance, Sakamoto et al. [81] found that Akt 
activity significantly increased following both acute submaximal and maximal intensity ET. 
Increases in Akt activity were accompanied by increases in Akt Thr308 and Ser473 
phosphorylation [81]. Beneficial effects of ET on anabolic pathway may depend on the 
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frequency of training. In support of this notion, Pasini et al. [103] Investigated the effects of 8 
weeks ET and training frequency (3 (EX3) or 5 days/week (EX5)) on anabolic pathways in 
the skeletal muscle of old rats. Aging was associated with reduced protein levels of IRS-1 and 
p-mTOR in aged control rats relative to the young control group. In response to ET, EX3 
resulted in reduced IR expression and increased IRS-1 levels compared with old control rats. 
However, EX5 up-regulated not only IRS-1 and COX activity but also p-mTOR expression 
[103]. Despite the fact that the precise mechanisms of the age-associated loss of muscle mass 
is not yet clear, it seems that PGC-1a plays a central role in this process [103, 122]. It has 
been shown that ET stimulates upstream signaling pathways involved in PGC-1a activity, 
including AMPK, p38MAPK, SIRT1 and p-CREB [131]. Mitochondrial biogenesis induction 
by PGC-1a is mediated by the coactivation a large spectrum of transcription factors, 
including Nrf1, Nrf2 through Tfam, which regulates mitochondrial DNA replication (Figure 
6) [50]. Furthermore an increase in mitochondrial function and biogenesis following ET has 
inhibitory effect on apoptosis initiation, therefore may help to preserve muscle quality and 
aerobic capacity during aging [98, 122]. However, it has also been suggested that ET may be 
counted as an effective therapy for sarcopenia not just by its effects on mitochondrial 
regulation and adaptation, but also by reduced catabolic pathways such as FOXO3A, 
myostatin and increased anabolic pathways such as IGF-1 and follistatin [56, 103, 124]. 
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Mitochondria biogenesis. PGC-1α is known as a master regulator of mitochondria biogenesis 
witch its gene expression is mediated by other factors such as AMPK, Sirt1, CaMk, NO and 
p38. PGC-1α gene expression along with the expression of Nrf1 and Nrf2 induce the 
expression of Tfam, which is imported into mitochondria. Tfam regulates the expression of 
the mtDNA gene products, including proteins such as cytochrome c oxidase subunit I    
(COX I) and also are involved in ATP synthesis. 
 
1.3.4. Hormone therapy 
 
Several hormonal treatments have been proposed for the treatment of sarcopenia including 
GH, IGF-1, testosterone and estrogens [59, 61, 65, 70, 104, 135]. However, controversial 
findings have been reported in the literature related to the effectiveness of hormone therapy 
on sarcopenia. More recently Brioche et al. [59] Investigated 8 weeks of GH administration 
(2 mg/kg/day) on some cellular markers of sarcopenia in old rats. The result was interesting 
as GH treatment led to a significant, 100% increase of IGF-1 in old animals. GH 
supplementation also prevented increased protein and DNA oxidation in old rats. Levels of 
PGC-1a, Nrf1, and Cyto C as well as citrate synthase activity were significantly lower in old 
animals than in young ones. These decrements were completely prevented by replacement 
Figure 6. Diagrammatic summary of endurance exercise training signaling pathways involved in 
mitochondria function in healthy mammalian skeletal muscle cell 
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therapy with GH. In addition, in response to treatment with GH, the significant decrease in 
Akt phosphorylation and phosphorylation of p70S6K were completely recovered in the old 
muscles. GH treatment prevented the elevation of p38 phosphorylation in the muscle of old 
animals. Myostatin and MuRF-1 are well-known agents involved in proteolysis. GH 
treatment prevented age associated increases in Myostatin and MuRF-1 [59]. Moreover, GH 
supplementation has been shown to inhibit apoptosis in aged skeletal muscle [61]. Marzetti et 
al. [61] found that aging was associated with an elevation of the expression of TNF-R1 and 
cleaved caspase-8 in the EDL muscle in response to GH administration, both of which were 
reduced in aged rats. However, they did not find any reduction in the content of cleaved 
caspase-3 and apoptotic DNA fragmentation by the hormonal intervention. They then 
concluded that the protective effect of GH supplementation was an early step of the extrinsic 
pathway of apoptosis in the EDL muscle and did not translate into an effective mitigation of 
the actual apoptotic events. However, independently of caspase activation, GH administration 
was associated with increased apoptotic DNA fragmentation in the soleus muscle [61]. 
However, there are some studies which did not find beneficial effects of GH therapy on 
muscle strength or muscle mass [34, 40, 136]. Based on the literature, it seems that GH 
supplementation is more effective in patients with GH deficiency or reduced GH secretion 
than in those with normal hormonal state [34]. Failure of the regulation of natural GH 
secretion or the induction of GH-related insulin resistance could be possible reasons for the 
ineffectiveness of GH treatment in improving muscle mass and strength in the elderly [40]. 
Regardless of the proposed benefits of GH therapy, numerous side effects have been 
reported, including soft tissue edema, gynecomastia, orthostatic hypotension, and carpel 
tunnel syndrome, which pose serious concerns especially in older adults [22, 40, 137]  . 
Another potential hormone treatment against sarcopenia in women is estrogen 
supplementation or hormone replacement therapy (HRT). Despite the availability of reports 
on the effectiveness of hormone therapy [138, 139], however, some studies did not report any 
significant impact [65, 104]. For instance, it has been demonstrated that there was no 
difference in the prevalence of sarcopenia in healthy independent older women who were 
long-term estrogen users compared with older women who did not use estrogen [104]. It has 
been suggested that HRT may protect against the loss of muscle mass, which occurs in the 
premenopausal period [22]. Differences in estrogen dose used, the duration of the study, 
levels of physical activity, diet and medications can be an explanation for the contradictory 
results between studies [65]. 
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Testosterone is another hormone that has been widely studied for its effects on strength and 
muscle mass in young and old people. Nevertheless, previous studies have reported 
conflicting results [22, 24, 40, 45, 66, 71, 91, 135]. Circulatory levels of testosterone are 
correlated with sarcopenia, muscle mass and function as well protein synthesis. It has been 
demonstrated that the bioavailable testosterone and the testosterone precursor, DHEA both 
drop with aging [45]. The exact mechanisms by which testosterone protects against 
sarcopenia of aging is still unclear. However, it can be due to, at least in part, the suppression 
of myostatin and the non-canonical TGF-ß pathway through stimulation of Notch signaling, 
together with the inhibition of JNK mediated apoptosis. Indeed, it has been suggested that the 
activation of Akt together with the inhibition of JNK may be critical for testosterone-
mediated protection against sarcopenia during aging [71, 135]. In this regard, it has recently 
been reported that suppression of myostatin signaling by testosterone supplementation 
reduces the extent of myonuclear apoptosis in the gastrocnemius muscle of old mice, while 
improving muscle mass and fiber cross-sectional area [91]. In support of the anabolic 
contribution of testosterone, a number of studies have reported an increased IGF-1 protein 
levels following testosterone administration [24, 45]. However, it has been reported that 
numerous side effects are associated with testosterone treatment, including increased risk of 
cardiovascular problems and pedal edema [71, 114].  
 
1.3.4.1. IGF-1 
 
It is crucial that an appropriate treatment strategy should be able to maintain muscle mass, 
reduce muscle loss and stimulate muscle regeneration that can counteract muscle wasting 
[140]. At least three major molecular processes are involved in the regulation of skeletal 
muscle hypertrophy: (1) satellite cell activity; (2) gene transcription; (3) protein translation 
[141]. Among the different growth factors, IGF-1 has been shown to be involved in many 
anabolic pathways in skeletal muscle as well as during muscle regeneration [43].  
IGF-1, also known as somatomedin C, is a 70–amino acid [142] that is similar to insulin in 
structure, sharing 50% amino acid identity. However, unlike the insulin gene, the single-copy 
IGF-1 gene locus encodes multiple proteins with variable amino- and carboxyl-terminal 
amino acid sequences [140]. IGF-1 exists in at least two isoforms as a result of alternative 
splicing of the IGF1 gene. IGF1Ea or systemic IGF-1, which is produced in both liver and 
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muscle tissues and IGF1Eb (rodent form) and IGF1Ec (human form) also known as mechano 
growth factors (MGFs), which are produced generally by skeletal muscle. Unlike MGFs, 
IGF1Ea is glycosylated, and this modification protects it from proteolysis and confers a 
relatively long half-life [60]. Most IGF-1 circulates in blood bound to one of the six high-
affinity IGF binding proteins (IGFBPs; IGFBP1 to IGFBP6), which have been shown to 
modulate IGF-1 availability for action on tissues [125]. It has been shown that overexpression 
of any of these IGFBP isoforms is associated with decreased in IGF-1 action by inhibiting it’s 
binding to IGF-1R [62]. In tissues, IGFBPs can both decrease or increase IGF1 actions either 
by detaching IGF1 from the IGF1R or by releasing free IGF1 available for receptor binding 
[60].  
A wide variety of tasks and functions have been related to IGF-1, such as regulation of both 
proliferative and differentiation responses in muscle cells, promotion and regulation of 
muscle growth, improvement of sprouting and axonal growth and cell survival on motor 
neurons, along with the prevention of motor neuron death [43, 142]. The positive regulatory 
effects of IGF-1 on muscle growth act on several levels, including satellite cell activation, 
gene transcription, and protein translation [143]. IGF-1 affect both hyperplastic and 
hypertrophic processes in skeletal muscle. The hyperplastic effect results in the proliferation 
of muscle satellite cells, while the hypertrophic effect results in increased synthesis of 
contractile proteins by existing myonuclei [34]. 
It has been shown that serum and skeletal muscle concentrations of IGF-1 are lower in older 
adults [144] and this low circulating IGF1 bioactivity and abnormalities of IGF1 may be 
involved in age-related sarcopenia [60]. Several studies have demonstrated that IGF-1 
administration reduce the age-related loss of skeletal muscle mass and strength likely through 
positive effects on neuronal function and by the prevention of apoptotic death, stimulating 
axonal sprouting and repair of damaged axons, increasing muscle oxidative enzymes and 
fatigue resistance [34, 45, 60, 71, 80, 134, 145, 146]. 
The exact molecular mechanism by which IGF-1 administration improves muscle mass and 
attenuates age-related muscle atrophy is not completely understood yet. However, it has been 
demonstrated that IGF-1 /PI3K/Akt and IGF-1 /ERK1/2 MAPK are the two main signaling 
pathways that are involved in IGF-1-induced cell protection [146]. 
After binding IGF to its receptor, a conformational change occurs, leading to activation of 
IRS-1 [62]. Phosphorylated IRS-1 can activate PI3-K, leading to Akt phosphorylation, which 
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in turn enhances protein synthesis through mTOR and p70S6 kinase activation and also 
mediating the antiapoptotic effects of the IGF1R through phosphorylation and inactivation of 
BAD. Indeed, activation of Ras by phosphorylated IRS-1 or SHC leads to the stimulation of 
the RAF-1/MEK/ERK pathway and downstream nuclear factors, leading to the induction of 
cell proliferation [60]. 
IGF-1 treatment can also increase protein synthesis and reduce protein degradation via 
downregulation of ubiquitin ligases. Activation of PI3K/Akt in turn leads to the 
phosphorylation and inactivation of FOXO transcription factors resulting in the reduction of 
MuRF1 and atrogin-1 expression thereby, a reduced protein degradation by the 26S 
proteasome in skeletal muscle [97] [147]. 
Taken together, it seems that the effectiveness of hormone therapy such as GH, estrogen, 
testosterone and IGF-1 on age-related loss of skeletal muscle mass is explained by the 
decreased the rate of protein degradation than increasing protein synthesis due to the 
modulation of IGF-1/FOXO, IGF-1/NFkB and IGF-1/ERK1/2 signaling pathways.  
 
1.3.5. Combination of exercise and nutritional and pharmacological supplementation 
 
It seems that exercise in combination with nutritional and pharmacological intervention is 
more effective against sarcopenia [32]. A wealth of data exists which demonstrate beneficial 
effects of the combination of exercise and nutritional interventions on skeletal muscle 
adaptation in older person [39, 46, 61, 66, 134]. For instance, it has been found that combined 
wheel running and mild CR significantly preserved a higher muscle mass/body mass ratio 
and fiber CSA [39]. Guo et al. [66] demonstrated that 2 months of testosterone administration 
together with low-intensity physical training (T/PT) improved grip strength, spontaneous 
movements, and respiratory activity in old mice. T/PT was associated with increased 
mitochondrial DNA copy number and expression of markers for mitochondrial biogenesis. 
Furthermore, 2 months of T/PT led to an increased expression of markers for mitochondrial 
fission-and-fusion and mitophagy and reduced tissue oxidative damage, while also improved 
muscle quality [66]. In contrast, Li et al. [134] have reported that there were no significant 
increases in Akt-1 and p70 S6K phosphorylation following an acute bout of ET and IGF-1 
injection in old mice [134]. However, the combination of exercise and IGF-1 has shown a 
modest effect on reducing aged-related wasting of skeletal muscle [148]. More recently, 
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McMahon et al. [148] investigated the effect of long term wheel-running on the prevention of 
sarcopenia in IGF-1Ea overexpressing transgenic mice compared with wild-type. Their 
results demonstrated that the combination of IGF-1 and exercise prevented the reduced mass 
of the quadriceps muscles in 28 months-old mice compared with wild type. However, there 
was no improvement in muscle function as assessed by grip strength [148]. 
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1.4. Summary of introduction  
 
Along with increased longevity, the prevalence and cost of sarcopenia are likely to rise [9]. It 
is associated with elevated risk of cardiac, pulmonary, and metabolic disease processes, 
which further contributes to the socioeconomic burden [126]. This global aging phenomenon 
has led to an increased morbidity and greater need for hospitalization and/or 
institutionalization. Healthy style of life is essential for older people to remain independent 
and to continue to actively take part in family and community life [14].  Developing new 
therapies and strategies to prevent and treat sarcopenia not only will help to improve the 
quality of life for patients, but also will help to reduce the economic and productivity burdens 
for society in general [9, 80].  
In this regard, in order to provide further insight into the development of more effective 
therapy, it is important to explore the mechanism and etiology of sarcopenia [42]. Among 
factors, free testosterone, physical activity, cardiovascular disease, IGF-1 in men and total fat 
mass and physical activity in women are significantly associated with muscle mass [149]. In 
spite of the documented benefits of aerobic exercise on cardiovascular and metabolic health 
for older adults, the influence of this type of exercise on skeletal muscle mass and function is 
less understood [128]. Furthermore, comparison of master athletes with sedentary controls 
demonstrated that training may not be sufficient to prevent skeletal muscle loss in older 
adults [46]. 
Therefore, it seems that factors, such as nutrition in conjunction with appropriate physical 
activity can help attenuate the age related physical and muscle mass decline and maintain 
quality of life [44]. 
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2. Objectives 
 
As mentioned in the previous chapter, reduced systemic anabolic hormone levels, especially 
IGF-1 and reduced mitochondrial efficiency with aging are two potential factors involved in 
sarcopenia. Despite strong evidence for the effectiveness of RT, the effect of ET on the 
prevention and reduction of age-related muscle loss is still not well understood. Furthermore, 
available data from previous studies on hormone therapy is ambiguous. Although, it has been 
shown that the combination of exercise and hormone supplementation is more effective than 
either alone in attenuating muscle atrophy.  
In our study, we aimed to elucidate the effects of endurance training with or without IGF-1 
administration on four of the main mechanisms, involved in the onset and progression of 
sarcopenia including, decreased rate of protein synthesis, increased protein degradation, 
alteration in mitochondrial biogenesis and increased apoptotic signaling. 
It was hypothesized that endurance exercise training alone and in combination with IGF-1 
treatment has beneficial effects on age-related muscle atrophy, and in general can attenuate 
the process of sarcopenia. 
The following assumptions were made:  
H1. Aging negatively influences the cellular markers involved in sarcopenia.  
H2. Endurance exercise training positively influences the cellular markers involved in 
sarcopenia.  
H3. IGF-1 administration enhances positive effects of endurance exercise on the cellular 
markers involved in sarcopenia.  
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3. Methods 
 
3.1 Subjects 
 
Fifteen young (3 months old) and 15 old (26 months old) male Wistar rats were used in the 
study.  We chose 26-month-old rats because previous studies have reported that sarcopenia is 
evident at 22 months age in this species [59, 150]. Subjects then were assigned to one of the 
following groups: young control (YC), young exercised (YE), young exercised and IGF-1-
treated (YEI), old control (OC), old exercised (OE), and old exercised and IGF-1-treated 
(OEI).  
The investigation was carried out according to the requirements of The Guiding Principles for 
Care and Use of Animals of the European Union and approved by the local ethics committee.  
 
3.2 Exercise protocol 
 
Exercised rats were introduced to treadmill running for 3 days; then for the next 2 weeks the 
running speed was set at 10 m/min, with a 5% incline for 30 min/day, 5 days per weeks. The 
running speed and duration of the exercise were gradually increased to 60% of VO2 max of 
the animals. Therefore, on the last week of the 6-week training program, young animals ran at 
22 m/min, on a 10% incline, for 60 min, whereas old animals ran at 13 m/min, on a 10% 
incline for 60 min (Figure 7). At the end of the study the animals were anesthetized with 
intraperitoneal injections of ketamine (50 mg/kg) and were sacrificed. This occurred two days 
after the last exercise session, to avoid any metabolic effects of the final run (Figure 8). 
Quadriceps muscle was carefully excised and stored at -80 ◦C. 
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Figure 7. The figures represent Speed, time and incline (ascent) of 6 weeks of endurance 
training on treadmill in young and old rats 
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OC (old control), YC (young control), OE (old exercise), YE (young exercise), OEI (old 
exercise and IGF-1 treatment), YEI (young exercise and IGF-1 treatment) and W (week). 
 
3.3 IGF-1 administration 
 
3.3.1 Alzet pump 
 
An Alzet pump (Alzet mini-osmotic pump model 2002. Durect Corporation #0000296) was 
inserted subcutaneously in all animals. Alzet pump operate via an osmotic pressure difference 
between a compartment within the pump, called the salt sleeve, and the tissue environment in 
which the pump is implanted. The high osmolality of the salt sleeve causes water to flux into 
the pump through a semipermeable membrane, which forms the outer surface of the pump. 
As the water enters the salt sleeve, it compresses the flexible reservoir, displacing the test 
solution from the pump at a controlled, predetermined rate. Because the compressed reservoir 
cannot be refilled, the pumps are designed for single-use only. The rate of delivery by an 
Alzet pump is controlled by the water permeability of the pump’s outer membrane. Thus, the 
delivery profile of the pump is independent of the drug formulation dispensed. Drugs of 
Figure 8. Schematic design of the study protocol 
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various molecular configurations, including ionized drugs and macromolecules, can be 
dispensed continuously in a variety of compatible vehicles at controlled rates. The molecular 
weight of a compound, or its physical and chemical properties, has no bearing on its rate of 
delivery by Alzet pumps. The volume delivery rate of Alzet pumps is fixed at manufacture. 
Alzet osmotic pumps are available with a variety of delivery rates between 0.11 and 10 µL/hr 
and delivery durations between 1 day and 6 weeks. While the volume delivery rate of the 
pump is fixed, different dosing rates can be achieved by varying the concentration of agent in 
the solution or suspension used to fill the pump reservoir. 
A more complete and technical explanation of the operation of Alzet osmotic pumps can be 
found in the http://www.alzet.com/. 
 
3.3.2. IGF-1 supplementation 
 
In the last 2 weeks of the study, treated animals received 5 μg/kg per day, 0.5 μL/hr IGF-1 
(Sigma #13769), whereas non-treated animals received saline via the pumps. With the help of 
the Alzet pumps, the 2-week supplementation of IGF-1 or saline could be maintained at 
constant flow, thus avoiding daily injections and their possible disturbance of behavioral and 
cognitive functions of the animals. 
3.4. Tissue preparation 
 
Frozen vastus lateralis samples were weighed (~100 mg) and homogenized (1:10 w/v) in ice-
cold buffer (20 mM Tris–HCl pH 8, 137 mM NaCl, 2% NP-40, 10% glycerol) supplemented 
with phosphatase and protease inhibitors. The homogenates were incubated at 4 °C for 30 
Figure 9. Schematic representation of an Alzet osmotic pump 
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min, and then centrifuged at 12,000 g for 20 min at 4 °C. Then, the supernatant was collected 
and Bradford assays were used to determine supernatant protein concentrations. Proteins 
were diluted in 2× SDS sample buffer (1:1) and then heated to 95°C for 5 minutes. 
 
3.5. Western blot analysis 
 
Ten to 20 μg of protein were electrophoresed on 6–15% vol/vol polyacrylamide sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels. Proteins were 
electrotransferred onto polyvinylidene fluoride (PVDF) membranes. The membrane was 
blocked with 5% milk–Tris-buffered saline with 0.1% tween-20 solution and then incubated 
with a primary antibody overnight at 4°C. Primary antibodies are described in Table 1 and 
were diluted 1:500 to 1:1000 with 5% milk–Tris-buffered saline with 0.1% tween-20. Blots 
were incubated with horseradish peroxidase–conjugated secondary antibody diluted 1:3000 
with 5% milk–Tris-buffered saline with 0.1% tween-20. After incubation with the secondary 
antibody, membranes were washed repeatedly and then were incubated with 
chemiluminescent substrate (Thermo Scientific, SuperSignal West Pico Chemiluminescent 
Substrate), and protein bands were visualized on X-ray films. The bands were quantified by 
ImageJ software and normalized to B-actin, which served as an internal control. 
 
3.6. Measurement of IGF-1 level 
 
After sacrificing the animals, blood was collected, supercharged ethylenediaminetetraacetic 
acid (EDTA) was added, and the samples were centrifuged at 3000 × g, for 10 min at 4°C. 
Plasma was separated and kept at −80°C. A Quantikine Mouse/Rat IGF-1 Assay Kit (R&D 
Systems, cat. no. MG100) was used to detect IGF-1 levels according to the description of the 
supplier. Briefly this assay employs the quantitative sandwich enzyme immunoassay 
technique. A monoclonal antibody specific for rat IGF-1 has been pre-coated onto a 
microplate. Standards, control, and samples were pipetted into the wells and any rat IGF-1 
present was bound by the immobilized antibody. After washing away any unbound 
substances, an enzyme-linked polyclonal antibody specific for mouse/rat IGF-1 was added to 
the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate 
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solution was added to the wells. The enzyme reaction yielded a blue product that turned 
yellow when the Stop Solution was added. The intensity of the color measured was in 
proportion to the amount of rat IGF-1 bound in the initial step. The sample values were then 
read off the standard curve. The optical density of each well were determined within 30 
minutes. microplate reader and wavelength was set to 450 nm and 570 nm respectively. 
 
Table 1. Description of primary antibodies used in the study 
Antibody/antigen Dilution ratio company Catalog number 
Follistatin 1: 500 Santa Cruz SC-30194 
Akt 1: 1000 Cell signaling #9272S 
p-Akt (Ser473) 1: 1000 Cell signaling #9271S 
mTOR 1: 500 Santa Cruz SC-8319 
pmTOR (Ser2448) 1: 500 Cell signaling #5536 
ERK1/2 1: 1000 Cell signaling #9102 
pERK1/2 (Thr202/Tyr204) 1: 500 Cell signaling #9106 
Myostatin (GDF-8) 1: 500 Santa Cruz SC-6884 
Ubiquitin 1: 1000 Cell signaling #3936 
MuRF1 1: 500 Santa Cruz SC-32920 
MuRF2 1: 500 Santa Cruz SC-49457 
PSMA6 1: 1000 Cell signaling #2459 
PGC-1α 1: 1000 Millipore ST1202 
SIRT1 1: 500 Santa Cruz SC-15404 
SIRT3 1: 500 Sigma S4072 
Nrf2 1: 500 Santa Cruz SC-722 
Cyto C 1: 1000 Santa Cruz SC-13560 
Cox 4 1: 500 Santa Cruz SC-69359 
TNF-α 1: 500 Santa Cruz SC-1350 
p53 1: 500 Santa Cruz SC-99 
Bcl-2 1: 500 Santa Cruz SC-492 
Bax 1: 500 Santa Cruz SC-493 
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3.7. Measurement of ROS level 
 
Intracellular oxidant and redox-active iron levels were estimated using modifications of the 
dichlorodihydrofluorescein diacetate (H2DCFDA) staining method. The oxidative conversion 
of stable, nonfluorometric DCFDA to highly fluorescent 2′7′-dichlorofluoorescein (DCF) was 
measured in the presence of esterases, as previously reported [151]. This assay approximates 
levels of reactive species, such as superoxide radical, hydroxyl radical, and hydrogen 
peroxide. The method has been widely used in the literature but does have the problem of not 
being particularly specific, and results can be strongly affected by release of labile iron or 
copper [152]. Briefly, the H2DCFDA (Invitrogen-Molecular Probes #D399) was dissolved to 
a concentration of 12.5 mM in ethanol and kept at −80 °C in the dark. The solution was 
freshly diluted with potassium phosphate buffer to 125 μM before use. For fluorescence 
reactions, 96-well, black microplates were loaded with 150 ul of 50 mM potassium phosphate 
buffer (13.969 g K2HPO4 + 2.71 g KH2PO4 in distilled water up to 200 ml, pH 7.4) to a 
final concentration of 152 μM/well. Then eight μl diluted tissue homogenates and 50 μl 125 
μM dye (20 ul 12.5 mM H2DCFDA in 1980 ul 50 mM potassium phosphate buffer) were 
added to achieve a final dye concentration of 25 μM. The change in fluorescence intensity 
was monitored every five minutes for 30 minutes with excitation and emission wavelengths 
set at 485 nm and 538 nm (Fluoroskan Ascent FL) respectively. Data obtained after 15 min 
were used. The fluorescence intensity unit was normalized to the protein content and 
expressed in relative unit production per minute. 
 
3.8. Statistical analyses 
 
Statistical significance was assessed by the IBM SPSS program version 21. Data were tested 
with Shapiro-Wilk’s W normality test. Parametric data were analyzed by one-way ANOVA, 
followed by Tukey’s post hoc test. Kruskal-Wallis ANOVA followed by Mann-Whitney U 
test was applied to evaluate the differences in non-parametric results in case of those 
variables where post-hoc analysis was required. The significance level was set at p < 0.05. 
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4. Result 
 
4.1 Cellular markers involved in protein synthesis 
 
The IGF-1/Akt and mTOR pathways are two evolutionarily conserved pathways that play 
critical roles in regulation of cell proliferation, survival, and energy metabolism. Moreover, it 
is possible that the increased IGF expression might contribute to skeletal muscle hypertrophy 
induced by follistatin [153]. Indeed, the IGF-ERK1/2 pathway can stimulate several 
substrates, such as p90RSK (p90 ribsosomal S6 kinase), resulting in the activation of 
transcription factors and the ribosomal subunit S6. ERK1/2 may also increase activity of 
kinases associated with protein translation, such as MAPK-interacting kinase 1 (Mnk 1) and 
its downstream substrate, eIF4E [39]. Therefore, we measured the IGF-1 level and 
phosphorylated and total protein content of Akt, mTOR, ERK1/2 and follisatin. 
The levels of circulating IGF-1 decreased with aging. There was significant increase in OEI 
compared with OC group (Figure 10). The expression levels of follisatin was also lower in 
OC vs. YC (p<0.05) while both exercise and IGF-1 treatment significantly increased (p<0.05) 
follistatin levels in OE and OEI (Figure 11). Total protein content of Akt and pAkt was 
higher (p<0.05) in OC vs. YC but there was no effect of exercise and IGF-1 interactions 
among groups (Figure 12B and Figure 12A respectively).  The results showed that protein 
levels of mTOR and pmTOR didn’t change with age, however, exercise resulted in an 
increase (p<0.05) in pmTOR among YE vs. YC, while significantly increases were observed 
in both mTOR and pmTOR levels (p<0.05 and p<0.01 respectively) following IGF-1 
supplementation in OEI vs. OC (Figure 13B and Figure 13A respectively). Nevertheless, 
aging and exercise training didn’t have significant effect on the ratio of pAkt: Akt (Figure 
12C) and pmTOR: mTOR (Figure 13C), however, IGF-1 treatment led to a significant 
increase (p<0.05) of pmTOR: mTOR in OEI compared to OE (Figure 13C), whereas YEI 
showed a significant reduction (p<0.01) compared to YE flowing IGF-1 administration 
(Figure 13C). Old subject showed lower level (p<0.05) of pERK1/2 (Figure 14B). Exercise 
training decreased the protein content of ERK1/2 (p<0.01) in YE vs. YC, while IGF-1 
treatment led to markedly reduction in OE and OEI (p<0.05 and p<0.01 respectively) (Figure 
14A). Aged subjects had significant increase (p<0.05) in pERK1/2: ERK1/2, while no effect 
of exercise and IGF-1 treatment was observed despite of a tendency for a decrease in OE and 
OEI, however, this ratio was lover (p<0.01) in YEI vs. YC (Figure 14C).  
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
 
 
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05. 
Figure 10. Effect of age, exercise and combination of exercise and IGF-1 administration on 
plasma level of IGF-1 
Figure 11. Effect of age, exercise and combination of exercise and IGF-1 administration on 
follistatin protein content 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC (old 
control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± standard 
error (SE) for 5 animals per group. (*) p < 0.05. 
A 
B 
C 
Figure 12. Effect of age, exercise and combination of exercise and IGF-1 administration on 
levels of pAkt (A), total Akt (B) and pAkt: Akt ratio (C) 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
A 
B 
C 
Figure 13. Effect of age, exercise and combination of exercise and IGF-1 administration on 
levels of pmTOR (A), total mTOR (B) and pmTOR: mTOR ratio (C) 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
 
 
A 
B 
C 
Figure 14. Effect of age, exercise and combination of exercise and IGF-1 administration on 
levels of pERK1/2 (A), total ERK1/2 (B) and pERK1/2:ERK1/2 ratio (C) 
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4.2 Cellular markers involved in protein degradation 
 
In recent years there has been a significant interest in growth and differentiation factor-8 
(GDF-8), or myostatin, which functions as a powerful negative regulator of muscle growth 
[154]. On the other hand, the ubiquitin proteasome system is one of the major pathways that 
regulates muscle protein degradation, playing a central role in controlling muscle size. 
MuRF1 and MuRF2 and proteasome subunits have been proposed to regulate protein 
degradation and gene expression in muscle tissues [80, 155, 156]. 
Therefore, we measured the expression levels of Myostatin, Ubiquitination, MuRF1, MuRF2 
and PSMA6. 
Myostatin expression levels was significantly higher in OC vs. YC (p<0.05) and it was lower 
(p<0.01) in YEI then YC (Figure 15). Ubiquitinated level was higher in OC vs. YC, whereas 
exercise and IGF-1 administration led to a significant increase in YE and YEI (p<0.05 and 
p<0.01 respectively) (Figure 16).  Expression levels of MuRF1 (Figure 17) and MuRF2 
(Figure 18) was significantly higher in OC then YC (p<0.05). Exercise training decreased 
MuRF1 and Murf2 levels in OE (p<0.05). Exercise also decreased MuRF2 protein content in 
YE (p<0.05) (Figure 18). Administration of IGF-1 also decreased MuRF2 levels in OEI 
(p<0.01) compared to OC (Figure 18) and increased (p<0.05) MuRF1 levels in YEI 
compared to YE (Figure 17). PSMA6 showed an increased with aging (p<0.05) and exercise 
training significantly increased its protein content both in YE and OE (p<0.05). IGF-1 
supplementation led to an evident increase (p<0.01) in YEI (Figure 19). 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
 
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
Figure 15. Effect of age, exercise and combination of exercise and IGF-1 administration on 
Myostatin protein content 
Figure 16. Effect of age, exercise and combination of exercise and IGF-1 administration on 
ubiquitinated protein content 
Ubiquitinated 
protein 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
Figure 17. Effect of age, exercise and combination of exercise and IGF-1 administration on 
MuRF1 protein content 
Figure 18. Effect of age, exercise and combination of exercise and IGF-1 administration on 
MuRF2 protein content 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
 
 
4.3 Cellular markers involved in mitochondria biogenesis 
 
Loss of mitochondrial functional integrity is centrally involved in muscle degeneration during 
aging and other atrophying conditions [55]. In particular, oxidative stress-induced damage to 
mtDNA impairs mitochondrial function, which can lead to further increases in ROS 
production and exacerbate the intracellular ROS-induced damage [157].  Therefore, we 
measured the ROS levels and expression levels of SIRT1, PGC-1a, SIRT3, Cyto C, Cox 4 
and Nrf2. 
OC showed elevated levels (p<0.05) of ROS compared to YC. There was no effect of 
exercise and IGF-1 treatment on ROS level (Figure 20). There was no difference between 
groups in PGC-1α and SIRT1 protein contents (Figure 21 and Figure 22 respectively). SIRT3 
level was significantly lower (p<0.01) in OC, while markedly increased SIRT3 protein 
content was observed in OE and OEI (p<0.05 and p<0.01 respectively) following exercise 
and IGF-1 administration (Figure 23). Cyto C and Cox 4 protein contents decreased with age 
(p<0.05) whereas endurance training led to a significant increase (p<0.05) of both Cyto C and 
Figure 19. Effect of age, exercise and combination of exercise and IGF-1 administration on 
PSMA6 protein content 
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Cox 4 in OE (Figure 24 and Figure 25 respectively). Nrf2 was also lower (p<0.01) in OC 
compared to YC, while exercise and IGF-1 treatment resulted an increase (p<0.05 and p<0.01 
respectively) in OE and OEI (Figure 26).  
 
 
 
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05. 
 
 
 
Figure 20. Effect of age, exercise and combination of exercise and IGF-1 administration on 
ROS level 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. 
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. 
Figure 22. Effect of age, exercise and combination of exercise and IGF-1 administration on 
SIRT1 protein content 
Figure 21. Effect of age, exercise and combination of exercise and IGF-1 administration on 
PGC-1α protein content 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
 
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05. 
Figure 23. Effect of age, exercise and combination of exercise and IGF-1 administration on 
SIRT3 protein content 
Figure 24. Effect of age, exercise and combination of exercise and IGF-1 administration on   
Cyto C protein content 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05. 
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
 
 
Figure 25. Effect of age, exercise and combination of exercise and IGF-1 administration on   
Cox 4 protein content 
Figure 26. Effect of age, exercise and combination of exercise and IGF-1 administration on    
Nrf 2 protein content 
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4.4 Cellular markers involved in apoptosis 
 
Available evidence supports the hypothesis that excessive myonuclear apoptotic elimination 
may drive the onset and progression of sarcopenia. The extrinsic pathway is initiated by the 
interaction of cell surface death receptors (e.g. tumor necrosis factor receptor, TNF-R) with 
their ligands (e.g. TNF-α) [91]. Recent studies suggest a fundamental role for p53 in 
organismal senescence. Several mouse models that display chronic p53-activation or chronic 
cell stress pathway activation display premature aging associated with pronounced tissue 
atrophy [158]. A critical event in mitochondrial-driven apoptosis is the formation of 
permeable membrane pores, regulated by the balance between competing anti-apoptotic Bcl-
2 family proteins, such as Bcl-2 and pro-apoptotic proteins, including Bax [159, 160]. 
Therefore, we measured the expression levels of TNF-α, p53, Bcl-2 and Bax. Also the ratio 
of Bax to Bcl-2 as an apoptotic index was calculated. 
There was no effect of age on TNF-α protein content, but administration of IGF-1 led to a 
significant reduction (p<0.05) in OEI vs. OC (Figure 27). p53 was higher (p<0.05) in OC 
than YC. Although there was a tendency of reduced p53 levels following exercise and IGF-1 
treatment, however, significant decrease (p<0.05) was only observed in YEI (Figure 28). Bcl-
2 protein content significantly decreased with aging (p<0.05), but IGF-1 supplementation 
markedly enhanced (p<0.05) its levels in OEI (Figure 29). Unlike in old subjects, YE and 
YEI showed a significant lowering (p<0.05 and p<0.01 respectively) of Bcl-2 levels in 
response to exercise and IGF-1 treatment (Figure 29). Bax protein content was obviously 
higher (p<0.05) in OC vs. YC. There was no significant effect of exercise and IGF-1 
supplementation, in spite of the tendency for a decrease in OE and OEI (Figure 30). The ratio 
of Bax to Bcl-2 as an indicator of apoptotic condition inside the cell, however, was 
significantly higher (p<0.05) in OC compared with YC. This ratio markedly decreased 
(p<0.05) following IGF-1 administration in OEI compared with OC (Figure 31). 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05. 
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05. 
Figure 27. Effect of age, exercise and combination of exercise and IGF-1 administration on 
TNF-α protein content 
Figure 28. Effect of age, exercise and combination of exercise and IGF-1 administration on p53 
protein content 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
   
YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05. 
- 
Figure 29. Effect of age, exercise and combination of exercise and IGF-1 administration on   
Bcl-2 protein content 
Figure 30. Effect of age, exercise and combination of exercise and IGF-1 administration on Bax 
protein content 
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YC (young control); YE (young exercised); YEI (young exercised IGF-1 treated); OC 
(old control); OE (old exercised); OEI (old exercised IGF-1 treated). Values are means ± 
standard error (SE) for 5 animals per group. (*) p < 0.05; (**) p < 0.01. 
Figure 31. Effect of age, exercise and combination of exercise and IGF-1 administration on 
apoptotic index (Bax: Bcl-2 ratio) 
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5. Discussion  
 
Sarcopenia, often defined as the age-related decrease in lean body mass, has become a topic 
of significant investigation since it affects so many people, healthy and ill, and utilizes 
significant medical resources. The direct costs approached $18.5 billion in the United States 
in 2000; by comparison, the annual cost of osteoporotic fractures in 1995 was $16.3 billion 
[161]. The precise reasons for sarcopenia are not well understood, however, the general age-
related decrease in hormonal and nervous system capacity are proposed as contributors with 
interactions between many systemic and local factors at the tissue level [162]. The purpose of 
this study was to examine age-related changes in cellular markers involved in sarcopenia in 
response to endurance exercise with or without IGF-1 treatment and to highlight some of the 
potential underlying factors that appear to contribute to the skeletal muscle wasting with 
aging. 
 
5.1 Aging negatively affected cellular markers involved in sarcopenia 
  
Maintaining muscle mass is achieved by balance between protein synthesis and protein 
degradation. An increase in muscle mass can come about due to either an increase in protein 
synthesis or a decrease in degradation, while a decrease in muscle mass can occur as a result 
of decreasing protein synthesis or increasing protein degradation [80]. Two major signaling 
pathways control skeletal muscle growth: the IGF1–Akt/PKB–mTOR pathway acts as a 
positive regulator of muscle growth, and the myostatin–Smad3 pathway acts as a negative 
regulator [72]. 
Our result demonstrated that aging was associated with a reduced level of IGF-1 and 
expression level of follistatin -two important protein synthesis stimulators in mammalian 
skeletal muscle- in old rat.  
IGF-1 acts mainly through three downstream signals that are mediated by PI3K-Akt. Each 
pathway plays a different role in various aspects of muscle growth. In the first pathway, IGF-
1 activates MAPK through PI3K-Akt, which eventually leads to the proliferation of 
myoblasts and satellite cells. PI3K-Akt-mTOR-P70S6K is the second pathway involving 
IGF-1 and its signals are transduced mainly through PI3K-Akt and mTOR to P70S6K. In the 
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third pathway, the activation of Akt inhibits the activities of GSK-3ß, thereby promoting the 
synthesis of specific proteins [163]. In accordance with our findings, age-related changes in 
systematic and local IGF and their binding proteins has been reported in human [164-167] 
and rat [168, 169]. Follistatin is also essential for skeletal muscle development and growth 
[170] and it is possible that the increased IGF expression might contribute to skeletal muscle 
hypertrophy induced by follistatin [153]. Hamrick et al. (Hamrick et al., 2012) reported that 
follistatin levels decreased by ~30% in mouse EDL with age. They then concluded that age-
associated loss of muscle mass in the predominantly fast-twitch EDL muscle may be due, in 
part to declining levels of follistatin [171]. Our result also demonstrated that the amount of 
Akt and pAkt was higher in old animals, while no effect of aging observed for the amount of 
mTOR and pmTOR. The phosphorylated and total amount of Akt and mTOR may be varied 
among muscle types in response to aging. Paturi et al. (Paturi et al., 2010) studied the effects 
of aging on muscle mass in the F344BN rat model. They compared Akt and mTOR in the 
slow soleus and fast extensor EDL muscles of 6, 30 and 36-month male rats. Their results 
were interesting. In soleus muscle the abundance of Akt protein was lower in 36-month-old 
relative to that observed in 6-month-old animals. However, compared to 6-month-old male 
animals the amount of p-Akt (Ser 473), p-mTOR (Ser 2448) were 47% and 28% lower and p-
Akt (Thr 308) was 38% higher in 36-month-old male animals. In the EDL muscle, relative to 
6-month-old male animals, the amount of Akt, mTOR, p-Akt (ser 473) and p-mTOR (Ser 
2448) were 38%, 182%, 73% and 91% higher in the 36-month-old male animals [172]. A 
decrease in IGF-1 mRNA by 45%, along with a 2.5-fold increase in total Akt, but not 
phosphorylated Akt, has been reported in older males compared to the young subjects [19]. 
This increase in phosphorylation and expression of Akt protein in muscle seems to be a 
compensatory response to aging. Akt plays a number of roles that may be important in 
sarcopenia. These roles can be included at least due to the decrease in apoptosis and protein 
degradation in skeletal muscle by increasing phosphorylation and inhibition of the pro-
apoptotic protein Bad and FOXO transcription factors, respectively [39]. The mTOR 
signaling pathway is also important for translation initiation and is therefore critical for 
muscle protein synthesis. One mechanism that activates mTOR signaling is the IGF-1/PI3k/ 
Akt pathway. Downstream effectors of mTOR signaling include p70s6k, 4E-BP-1, eIF-4E, 
and S6K [45]. It has been reported that a reduced amount of mTOR, pmTOR, S6 ribosomal 
protein are present in aged rodents, consequently impairing mTOR signaling and mRNA 
translation. Therefore, impairment in protein synthesis in aged muscle is evident [173-175]. 
However, there are some studies, which reported increased amounts of phosphorylated 
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mTOR and p70S6K in the tibialis anterior and increased level of phosphorylated p70S6K, 
eukaryotic initiation factor 2 subunit B (eIF2B) activity in gastrocnemius muscle of senescent 
rats [176, 177]. Our finding showed that there was no difference in phosphorylated and total 
expression of mTOR protein between old and young subject. Therefore, aging did not 
commonly modulate the PI3-K/Akt/mTOR-linked molecules in skeletal muscle under 
sedentary conditions [77], suggesting that other pathways, such as the MAPK signaling 
pathway should also be considered. MAPK signaling transduction pathway acts in a wide 
variety of physiological and pathophysiological cellular processes including cell proliferation, 
differentiation, apoptosis, migration, inflammation, metabolic disorders and diseases. In 
skeletal muscle, it plays a critical contribution in muscle fiber specialization, muscle mass 
preservation, damage-induced muscle regeneration and muscle diseases. MAPK pathway 
consists of at least 4 subfamilies that include ERK 1/2, p38a/ß/?/ d MAPK, JNK 1/2/3, and 
ERK5 [178]. The ERK1/2 pathway is involved in activation of several substrates, such as p90 
ribosomal S6 kinase (p90RSK), leading to the activation of transcription factors. ERK1/2 can 
also activate kinases associated with protein translation such as Mnk 1 (MAPK-interacting 
kinase 1) and its downstream substrate, eukaryotic initiation factor 4E (eIF4E) [39]. We 
found that baseline content of ERk1/2 was lower in aged rats whereas no difference was 
observed in pERK1/2 between the young and old groups, however, activity of ERK1/2 
(pERK1/2: ERK1/2 ratio) was higher in aged rats compared with their young counterparts. 
Recently, a study investigated activation and total protein content of MAPK signaling 
cascade proteins (ERK 1/2, p90RSK, Mnk 1, eIF4E, p38 MAPK, JNK/SAPK, and MKP 1) at 
rest and following exercise in sedentary young and old men. The results demonstrated a 
higher baseline levels of ERK 1/2, p90RSK and Mnk 1 in the old men compared with young 
counterpart [179].  
Among the several pathways which are participated in the pathogenesis of muscle mass 
maintains, MAPKs is considered for having an important role. MKP-1 is a phosphatase 
which by dephosphorylating acts as an inhibitor for MAPKs. It has been found that 
overexpression of MKP-1 in skeletal muscle fibers induced profound muscle fiber atrophy 
possibly through the ubiquitin-proteasome pathways. This anti-atrophic effect of MAPKs 
may be through ERK1/2 signaling pathway. It is believed that ERK1/2 pathway counteracts 
muscle wasting through enhanced protein synthesis by its control of ribosomal RNA gene 
expression [178]. These findings may explain the higher baseline levels of ERK 1/2 old rat 
81 
 
from the current study, possibly as a compensatory response of skeletal muscle along with 
aging. 
As mentioned above, age related increased in protein degradation in skeletal muscle plays an 
important role in sarcopenia [77, 87]. We found much higher level of Myostatin, 
ubiquitination, MuRF1, MuRF2 and proteasome subunit PSMA6 expression in old subjects 
compared with young ones. Our finding are in line with previous studies which reported 
increasing TGF-ß/myostatin pathways [19, 135, 180-182] and ubiquitin proteasome system 
activity [100, 177, 183, 184] in old humans and animals. Myostatin and TGF-ß are generally 
located in an inactive form in the muscle extracellular matrix and after activation can bind to 
their receptors resulting in activation of the Smad2/3 and TAK1/p38 MAPK signal 
transduction cascades. Smad2 and Smad3 are transcription factors which are able to bind 
DNA and directly regulate the expression of target genes. Smad2/3 can also bind to the 
FOXO family to regulate gene expression. In addition, myostatin signaling can suppress the 
IGF-1/PI3K/Akt axis and reduce p70S6K activation [80]. 
The UPS is mostly responsible for the degradation of misfolded proteins, as well as long-
lived proteins. The substrate specificity of the ubiquitin conjugation cascade is mediated by 
hundreds of E3 ubiquitin protein ligases. MuRF proteins MuRF1, -2, and -3 comprise a 
subfamily of the RING-finger E3 ubiquitin ligases that are expressed specifically in cardiac 
and skeletal muscle. The main target of MuRF1 is titin at the M-band of the sarcomere that 
has an important role in maintaining the stability sarcomeric M-line region. MuRF2 can also 
bind to the titin kinase domain and is contributed in the serum response factor signal 
transduction pathway [185]. Since it has been demonstrated an enhanced proteolysis by the 
UPS in aged skeletal muscle, which may enhance their capacity to eliminate misfolded 
proteins, hence they appear to be involved in the sarcopenia [183]. Nevertheless, it should be 
noted that not all studies have reported significant age-related differences in Myostatin and 
MuRF1in protein and mRNA expression at baseline [19, 186-188]. One possible reason for 
these inconsistency can be due to differences in the age of the subjects between the studies 
that can be related to the degree of muscle mass loss, because individuals >80 years old have 
a greater prevalence of sarcopenia, and more severe muscle atrophy compared to individuals 
only a decade younger [39]. 
There are a number of lines of evidence supporting the hypothesis that mitochondrial 
dysfunction is a characteristic of human aging in skeletal muscle [51]. The mechanism for 
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age-associated decline of mitochondrial biogenesis and dysfunction is still unknown and 
under intense investigation [131]. Currently, it is generally accepted that ROS play a primary 
role in the aging process, mitochondrial production of ROS has been shown to increase in 
skeletal muscle along with increasing age [2, 27]. Excessive production of ROS has been 
shown to be a key signal for the onset of several musculoskeletal diseases [189]. Old animals 
in our study showed much higher level of ROS compared to young animals. ROS also 
stimulate negatively the mitochondrial biogenesis [68]. These include decreased 
mitochondrial biogenesis and turnover, and oxidative damage to mitochondrial enzymes, 
structural proteins and membrane lipids. It has been suggested PGC-la plays a critical role in 
age-related reduction of mitochondria biogenesis [93].  
However, there was no significant change in PGC-1a protein content between old and young 
rats in our study. This finding can be supported by the notion that overall levels of PGC-1a 
protein did not change with age [190]. In other hand, however, the changes in mitochondrial 
energy metabolism may be due to a decline in PGC-1a activity with age [191]. In contrast to 
our result, Kang et al, reported PGC-1a mRNA expression and protein content decreased by 
35% and 19% (P < 0.01 and P < 0.05 respectively) in old rats compared to young rat rats 
[131]. Koltai et al. also found a lower amount of PGC-1a in old rats than young ones [192]. 
Different muscle types that were used in these studies (soleus) [131, 192] compared to our 
study (vastus lateralis) can explain, at least in part, this difference observed for PGC-1a 
protein content in responses to aging. Previously it has been shown that type II fibers are 
vulnerable to age-associated atrophy in humans and in non-human primates, while type I 
fibers generally are not. These data suggest that fibers of distinct structural and metabolic 
profiles are differentially impacted by age [190]. Among the upstream enzymes and 
transcription factors known to control PGC-1a gene expression and activity, such as AMPK, 
p38MAPK, SIRT1 and CREB [131], we found that SIRT1 level did not show a significant 
age-related change, thus, its unchanging expression could be a reason for the lack of 
difference in PGC-1a protein level between old and young age in current study. In support of 
our findings, Kang et al.  [131] reported that there was no difference in expression levels of 
SIRT1 in muscle of old vs. young rats. In our study we did not measure SIRT1 and PGC-1a 
activity, however, pervious study reported that levels of nicotinamide 
phosphoribosyltransferase (NAMPT) were lower in tissue from old animals. NAMPT is a key 
enzyme in the NAD salvage pathway that positively regulates SIRT1 activity in skeletal 
muscle. A decline in NAMPT would be predicted to lower SIRT1 activity, which would 
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negatively influence PGC-1a localization and activity [190]. SIRT1 deacetylates and 
activates PGC- 1a [193], while SIRT3, another one of mammalian Sirtuins, which is localized 
to mitochondria plays a major role in deacetylating and modifying the enzymatic activities of 
several mitochondrial proteins [194]. In agreement with previous studies [193, 195, 196], we 
found a significant reduction of the protein content of SIRT3 in aged rats compared to 
younger ones. SIRT3, a mitochondrial NAD+-dependent deacetylase, has been shown to play 
a crucial role in controlling cellular ROS homeostasis [197]. SIRT3 deacetylates and 
activates many mitochondrial enzymes involved in fatty acid ß-oxidation, amino acid 
metabolism, the ETC, and antioxidant defenses [198]. Interestingly, this decreased levels of 
ROS and SIRT3 in our study was associated with a remarkable reduction in Cyto C and Cox 
4 in old subjects. In consistent with our results, data reported from a study on 146 healthy 
men and women aged 18–89 years demonstrated that mtDNA and consequently abundance of 
mRNA for Cox 4, which is encoded by mtDNA and nuclear DNA, declined with advancing 
age [199]. Kontani et al. [200] Found that Cox 4 protein level was also reduced considerably 
in the aged gastrocnemius muscles with atrophy [200]. Moreover, COX activity, an 
established biochemical indicator of mitochondrial volume, was 30% lower (P < 0.05) in the 
muscle from old, compared to young animals [201]. On the other hand, our further 
measurements showed that Nrf2, a nuclear transcription factor that activates the proximal 
promoter of the rat Cox 4 gene significantly decreased with aging [202]. Taken together, our 
findings support age related mitochondrial dysfunction in the old rat. 
Apoptosis have also been shown as a potential mechanism involved in sarcopenia [43, 91, 
118]. Oxidative stress, chronic inflammation, and impaired insulin sensitivity seems to be 
potential candidates for the activation of myonuclear apoptosis at old age [43]. Proteolytic 
enzymes, known as caspases, perform the dismantling of the cell and are normally present as 
inactive zymogens (procaspases). Upon appropriate stimuli, initiator caspases (i.e., caspase-8, 
caspase-9, caspase-12) are activated, leading to the activation of effector caspases (i.e., 
caspase-3, caspase-6, caspase-7) responsible for the cellular degradation and DNA 
fragmentation via a caspase-activated DNase (CAD) [31]. Two major pathways of caspase 
activation are distinguished based on the extrinsic or intrinsic origin of the death-inducing 
stimulus. The extrinsic pathway is initiated by the stimulation of cell surface death receptors 
(e.g. TNF-R) by their ligands (e.g. TNF-α). The intrinsic pathway is activated through the 
triggering signaling from mitochondria or the endoplasmic reticulum [91]. The release of 
apoptotic triggers appears to be modulated through two mechanisms: (1) the balance of 
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proapoptotic (e.g., Bax) and anti-apoptotic proteins (e.g., Bcl-2), particularly from the Bcl-2 
family, which control OMM stability and form the mitochondrial apoptosis-induced channel 
(MAC), and (2) the mPTP [52]. The balance between these mediators (e.g., Bax-to-Bcl2 
ratio) is considered a fundamental control point for the cell fate by regulating OMM stability 
as Bax promoting mPTP opening, while the antiapoptotic Bcl-2 possess an inhibitory effect 
[31]. The mPTP opening then results in the release of apoptotic factors that are stored in the 
intermembrane compartment [93]. In addition, p53 can also promote apoptosis via inducing 
Bax activity [203-205]. 
Our result demonstrated that a significant increase in p53 protein content was associated with 
a remarkably decreased Bcl-2 and a significant increase of Bax protein expression in old vs. 
young subjects. Consequently, cell antiapoptotic ability (Bax to Bcl-2 ratio) was also lower in 
the aged rats. However, no age-related difference was found in TNF-α protein level. 
Increased p53 content observed in the current study would be probably due to much higher 
levels of ROS in aged rats compared to young ones.  
Recent studies have indicated that cellular concentration and distribution of p53 has different 
cellular function, and ROS can act as an upstream signal that triggers p53 activation [206]. In 
agreement with our findings, a number of studies reported increased expression of Bax and 
reduced levels of Bcl-2 in the skeletal muscle of old rodents [55, 98, 207, 208]. In contrast, 
however, some investigators have found that Bcl-2 family proteins increased in old muscles 
[209, 210].  These elevations of Bcl-2 detected in aged muscles could be interpreted as a 
compensatory response to aging. It was demonstrated that increased expression of Bcl-2 in 
the gastrocnemius muscle of old mice was paralleled by enhanced serine-phosphorylation and 
subsequent inactivation of Bcl-2, which prevented its anti-apoptotic actions in spite of the 
elevated expression [55].  
 
5.2 Endurance training positively reversed some cellular markers involved in 
sarcopenia 
 
Physical inactivity is a significant contributing factor to age-related sarcopenia. It is well 
established that sedentary elderly have less skeletal muscle mass and high prevalence of 
disability [4]. Exercise training is considered as a simple, feasible, and inexpensive strategies 
available to prevent the onset of sarcopenia and reduce the rate of functional decline [46]. 
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Previous studies have clearly shown the effectiveness of resistance-type exercise 
interventions on skeletal muscle mass and functional capacity in the elderly [211-217]. In 
addition, endurance type exercise training has been shown to improve muscle mass and 
strength, and increase performance capacity in both the young and elderly [75, 103, 126, 128, 
218-223].  
The data from our study showed that 6 weeks endurance exercise training did not lead to 
significant changes in the level of IGF-1 and protein content and phosphorylated of Akt, 
pAkt, mTOR, pmTOR, pERK1/2, but significantly increased the amount of follistatin and 
decreased pERK1/2 in the old exercise group compared to old control.  
Number of studies found an increased size and contractile properties of old slow (MHC I) 
and fast (MHC IIa) myofibers, following endurance training [128, 220, 224]. One study 
reported that 12 wk of cycle ergometer training increased MHC I fiber size 16 +/- 5% and 
MHC I peak power 21 +/- 8% while MHC IIa peak power was unaltered [220]. In one other 
study, 78 healthy, previously untrained men and women aged 19-87 years were evaluated 
before and after 4 months of bicycle training or control (flexibility) activity. They found that 
mixed muscle protein synthesis declined with age at the whole body level at the rate of 3.5% 
per decade. Exercise training improved overall aerobic capacity 9%, while mixed muscle 
protein synthesis increased by 22%. This study also demonstrates that aerobic exercise can 
enhance muscle protein synthesis irrespective of age [222]. However, the mechanism(s) by 
which endurance exercise affects aged skeletal muscle remain poorly understood. A number 
of studies have examined the effect of endurance training on IGI-1 and IGF-1 binding 
proteins among older subjects [45, 125, 129, 225]. Poehlman et al. studied 8 weeks cycling 
exercise, three times per week at 75% of their Vo2max, on older individuals. They found that 
endurance training significantly increased fasting levels of IGF-1only in men (r = .79, P < 
.02), while there was no mean group change in IGFBP-1 or IGFBP-3 [129]. A comparison 
between sedentary middle-aged (MAsed) and active middle-aged (MAcy)- almost 12 hours 
of cycling per week for the past 11 ±1.4 (SE) years- showed that basal IGF-1, IGFBP-1, and 
IGFBP-3 were higher (61%, 127%, and 21%, respectively, P <0.05) in MAcy than in MAsed 
[225]. In addition, an increased activity of the GH/IGF-1 system by endurance training in 
middle-aged men has also been reported [125].   
However, there are some documents which reported that endurance training did not lead to 
remarkable changes in muscle mass, maximal strength, and power [112, 127, 221, 223]. 
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Possible explanations for this difference could be due to differences in age (middle-age vs. 
aged) and gender (men vs. women) of the subjects, and especially the various exercise 
training protocols used (i.e., intensity and duration). For example, 2 weeks of endurance 
training at moderate intensity did not increase IGFBP-3 in an aged sedentary population, 
whereas specific, intense training in elite athletes performed over several months increased 
this binding protein [225]. In accordance with our results, Gielen et al. [127] found that 4 
weeks endurance training on treadmill did not change muscle mRNA levels of IGF-1 in 
elderly men. Also, LeBrasseur et al. [112] reported that 4 weeks treadmill exercise training 
did not change Akt protein abundance and phosphorylation of Akt relative to total in aged 
muscle of old mice. Furthermore, Pasini et al. [103] investigated the effects of treadmill 
exercise and training frequency on anabolic pathways in skeletal muscle of old rats. Aged 
male Wistar rats were trained on a treadmill for 3 (EX3) or 5 days/week (EX5) during 8 
weeks and compared with age-matched sedentary controls (SED). Compared with SED rats, 
the expression of p-mTOR was unaffected by EX3. However, EX5 up-regulated p-mTOR 
expression [103]. Taken together, these data suggest that IGF-1/Akt/mTOR pathway is not 
the main target of endurance exercise training and its effects on skeletal muscle protein 
synthesis probably occur through other pathways involved in sarcopenia. In this regard, we 
found that follistatin protein amount significantly increased in old rats after endurance 
training compared with control.  
Follistatin is expressed in different tissues and acts as an antagonist of different family 
members of TGF-ß [82]. Increased protein synthesis can also be due to decrease in the 
protein breakdown as a result of inhibitory extracellular binding proteins, such as follistatin, 
whose effect is even greater than the lack of myostatin [72]. In agreement with our result, 
Hansen et al. [124] found that endurance exercise induces increased levels of follistatin in the 
circulation. The kinetics revealed that plasma follistatin increased markedly during the 
recovery after exercise both in humans and in mice. The increase in plasma follistatin after 
exercise appears to be dependent on both the intensity and duration of exercise. Thus, 3 h of 
bicycling exercise induced a 7-fold increase in plasma follistatin, whereas 2 h of one-legged 
knee extensor exercise only increased plasma follistatin by 2-fold. The exercise-induced 
increase in follistatin may also be dependent on the muscle mass recruited during the exercise 
bout [124]. 
Sarcopenia is the result of imbalance between protein degradation and synthesis, Although 
the exact contribution of each of these factors is unknown, however it is believed that the 
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increase in muscle proteolysis associated with aging can make a significant contribution in 
the development of muscle degradation [90]. Unlike protein synthesis, a larger number of 
studies have examined the effects of Endurance Training on the mechanisms involved in 
protein breakdown in aged-skeletal muscle and conflicting results have been reported [112, 
126, 127, 226, 227].  
The results of our study revealed that endurance training significantly decreased protein 
expression of MuRF-1 and Murf-2 and increased PSMA6 levels in aged rats, while no change 
was found in Myostatin and ubiquitination levels. Similar reduction in MuRF-2 content and 
elevation in PSMA6 level has been seen in young rats following training.  
Our results are in line with previous studies, which demonstrated reduced levels of mRNA 
and protein expression of MuRF-1 [112, 127] and no changes in myostatin [127] following 
endurance exercise in old humans and animals. The effect of myostatin is mediated by the 
transcription factors Smad2 and Smad3, which also interact with IGF1-Akt signaling [63]. 
LeBrasseur et al. also found that Smad3 protein abundance did not change following 4 weeks 
endurance training in old mice [112]. Nevertheless, in contrast, some studies have reported 
reduced levels of myostatin mRNA and protein expression in response to endurance exercise 
[126, 226, 227]. One possible reason for these conflicting results could be due to differences 
in muscle fiber type used in these studies. For example, Ko et al. [227] showed that treadmill 
exercise improved muscle mass and strength through suppression of myostatin mRNA and 
protein expression in the gastrocnemius (versus vastus lateralis muscle in our study). Protein 
synthesis and muscle adaptation are regulated differently with aging in different muscle types 
[172] and signal transduction protein concentrations vary between fast and slow muscles 
[228]. To our knowledge, this is the first investigation to report significant reduction in 
protein content of MuRF-2 in aged skeletal muscle in response to endurance training. It has 
been indicated that combined inhibition of MuRF1/MuRF2 can lead to stimulation of striated 
muscles anabolism and protestation muscles from sarcopenia during aging [155]. 
Aging is characterized by a progressive deterioration in aerobic exercise capacity and this 
attenuation in cardiovascular efficiency may be linked to reduced quantity or quality of 
skeletal muscle mitochondria [122]. Endurance training can correct the age related decline in 
enzyme activities or protein content in older individuals [53]. Muscle mitochondrial 
adaptations to aerobic training appear to be the result of exercise-induced increases in the 
transcription of mitochondrial genes [122]. 
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The findings of our study revealed that 6 weeks endurance training significantly increased 
protein expression of SIRT3, Cyto C, Cox 4 and Nrf2 while there was no effect of exercise 
training on ROS levels and the amount of SIRT1 and PGC-1α. 
Among the upstream enzymes and transcription factors known to control PGC-1α gene 
expression and activity, such as AMPK, p38MAPK, SIRT1 and CREB [131], we found that 
SIRT1 levels did not show a significant change in response to exercise training. Thus, this 
lack of response could be a possible reason for the unchanged PGC-1a protein expression 
with endurance training at old age. SIRT1 is known to activate PGC-1a by deacetylation, and 
SIRT1/PGC-1a work as regulatory axis to control mitochondrial function during aging [229]. 
Previous studies have reported conflicting results regarding the effect of endurance training 
on PGC-1a activity and expression in old human and rodents. In agreement with our result, 
findings of LeBrasseur et al. [112] Showed that 4 weeks endurance training did not change 
PGC-1a protein expression in 24-month-old male mice. In contrast, 12 weeks endurance 
training showed a 2.3 and 1.8-fold higher PGC-1a content in old exercised than old and 
young control rats, respectively (P < 0.01) [131]. Moreover, after 12 weeks of aerobic 
exercise training on a cycle ergometer in older women, PGC-1a protein content was 20 ± 5% 
lower (p < 0.05) [126]. A possible explanation for these conflicting results could be due to, at 
least in part, differences in muscle types that have been examined in these studies (e.g. soleus 
muscle [131] vs. vastus lateralis muscle in [126] and our study). Skeletal muscle fibers are 
classified into three types: type I, type IIa, and type IIb [230] and PGC-1α is expressed 
preferentially in muscle enriched in type I fibers [231]. Coactivation of PGC-1a induces Nrf1 
and 2, which promote the expression of most nuclear-encoding mitochondrial proteins, as 
well as Tfam that directly stimulates mitochondrial DNA replication and transcription [131]. 
Nrf2 downstream signaling are believed to be involved in redox homeostasis preservation and 
protection of the structure and function of skeletal muscle [189]. Nrf2 is regarded as a master 
regulator of antioxidant transcription and binds to the antioxidant response element (ARE) in 
the promoter of target antioxidant genes and tightly regulates its transcription [232]. 
Furthermore, SIRT3 activity can reduce ROS levels by directly modulating key antioxidant 
enzymes, thereby acting as a shield against oxidative damage. SIRT3 exerts its antioxidant 
effects in an interaction with manganese superoxide dismutase (MnSOD) and isocitrate 
dehydrogenase 2. MnSOD is the primary mitochondrial antioxidant enzyme that converts O•-
2 to H2O2, which is further converted to water by catalase. The ability of MnSOD for 
scavenging ROS in mitochondria can be significantly enhance due to directly deacetylation 
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by SIRT3 [198]. In line with previous studies [233-236], our results demonstrated that protein 
contents of both Nrf2 and SIRT3 significantly increased, suggesting an adaptive response in 
the intracellular antioxidant system following endurance training in old rats. Indeed our 
findings showed improved mitochondrial biogenesis due to remarkably increased Cyto C and 
Cox 4 in old exercised rats. Kang et al. reported that a treadmill running program for 12-
weeks resulted in 1.4-fold increase in Cyto C protein content (P < 0.05) in old trained vs. old 
sedentary rats [131]. Indeed, 12 weeks of aerobic exercise training on a cycle ergometer in 
nine older women (70 ± 2 years) demonstrated that Cox 4 was elevated 33 ± 7% after 
training, suggesting that the training program resulted in mitochondrial biogenesis [126]. 
Moreover, an increased muscle protein content of Cox 4, the marker of mitochondrial 
biogenesis, has been reported in response to endurance training among old humans and 
rodents [56, 103, 121]. Taken together, our result indicates that endurance exercise training 
improved mitochondrial biogenesis in old rats. 
In connection with the factors involved in sarcopenia, accumulating evidence suggests that 
enhanced activation of apoptosis takes place in aged skeletal muscle, likely contributing to 
the development of sarcopenia [93]. In general, aging is associated with increased 
mitochondrial dysfunction and pro-apoptotic signaling through the mitochondrial Bcl-2 
pathway. The ratio of pro- to anti-apoptotic Bcl-2 family proteins (e.g., Bax/Bcl-2) can be 
used as an indicator of cell apoptosis which is involved in myonuclei integrity and cell 
survival by controlling mitochondrial membrane permeability and activation of caspases. 
Exercise training is well known to convey benefits across a spectrum of biological processes, 
including adaptations in apoptotic pathways [237]. A number of studies have investigated the 
effect of endurance training on cellular apoptotic markers in old subjects [61, 98]. One study 
found that twelve weeks of treadmill exercise training increased anti-apoptotic Bcl-2, while 
markedly reduced Bax, and Bax/Bcl-2 ratio in the white gastrocnemius and soleus muscles of 
old rats [98]. However, in contrast, our results indicated that six weeks of treadmill exercise 
training did not change the protein contents of TNF-α, p53, Bcl-2, Bax and Bax/Bcl-2 ratio in 
the vastus latralis muscles of old rats. In addition to differences in the duration of the studies 
(12 weeks [98] instead 6 weeks in our study), another important potential factor for these 
inconsistent results may be due to the differences in muscle fiber types used. In this regard, 
Marzetti et al. [61] reported that type I muscle fibers, like soleus, are less susceptible to age-
associated apoptosis than type II fibers and therefore less likely to be affected by short-term 
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exercise training. However apoptotic potential is elevated in type II muscle fibers at old age 
and may be attenuated by interventions, such as life-long CR and ET [61]. 
In summary, our results indicated that 6 weeks endurance training positively regulated some 
cellular sarcopenic markers by reducing proteins involved in muscle proteolysis and 
increasing some proteins involved in mitochondria biogenesis in the vastus latralis muscle of 
old rats.  
Changes in fiber-type-specific myosin isoform and in mitochondrial energy metabolism point 
to PGC-1α regulated pathways in the metabolic transition at mid-age. Although overall levels 
of PGC-1α protein did not change with age, the changes in mitochondrial energy metabolism 
are consistent with a decline in PGC-1α activity with age. Immunohistological detection of 
PGC-1α indicates that its localization to the nucleus is impaired with age, suggesting a 
possible mechanism for diminished PGC-1α activity. The NAD-dependent deacetylase 
SIRT1 is an activator of PGC-1α [238-240] that can also regulate PGC-1α cellular 
distribution [241]. The lower NAD/NADH ratio detected in mid-age is predicted to 
negatively influence SIRT1. Attempts to measure levels of SIRT1 in tissue homogenates 
were not successful; however, levels of NAMPT were lower in tissue from old animals. 
NAMPT is a key enzyme in the NAD salvage pathway that positively regulates SIRT1 
activity in skeletal muscle in mice [242]. A decline in NAMPT would be predicted to lower 
SIRT1 activity, which would negatively influence PGC-1a localization and activity. The 
finding that subsarcolemmal mitochondria were more sensitive to the impact of age is of 
interest because this population of mitochondria is known to be most responsive to changes in 
PGC-1α activity [190, 243]. 
 
5.3 Endurance training combined with IGF-1 administration positively 
affected some cellular markers involved in sarcopenia 
 
Our third study question was about the effect of combination of endurance training and IGF-1 
treatment on some cellular markers involved in sarcopenia. To the best of our knowledge, our 
study is the first, which has studied the effects of combined endurance training and IGF-1 
treatment on skeletal muscle cellular markers of sarcopenia in old rats. Just recently, one 
study examined the effect of IGF-1 expression within skeletal muscles with or without 
exercise on the prevention of sarcopenia [148]. They used four-month-old male transgenic 
91 
 
mice that were assigned to be sedentary, or had access to free-running wheels, until 18 or 28 
months of age. They found that in wild-type mice, the mass of the quadriceps muscles was 
reduced at 28 months, but exercise rescued such loss, without affecting the CSA of the 
myofibers. In contrast, they reported that elevated IGF-1 level alone was insufficient, while 
the combination of exercise and IGF-1 was augmentative in maintaining the diameter of 
myofibers in the quadriceps. Their findings showed that exercise and IGF-1 had a mild effect 
on reducing aged-related skeletal muscle loss, but there is no improvement in muscle function 
when assessed by grip strength [148]. However, previous studies investigated the effects of 
combined endurance training and administration of testosterone [66], growth hormone [244, 
245], fresh red orange juice (ROJ) [246], melatonin [247], resveratrol [248] , 17 beta-
estradiol and perindopril [249], and caloric restriction [250] on aged skeletal muscle in 
humans and rodents. 
We found that two weeks of IGF-1 administration significantly increased serum IGF-1 levels 
in OEI compared to OC. Consequently, this lead to a significant increase in protein 
expression of follistatin, mTOR and pmTOR and reduction in pERK1/2 following 
combination of endurance training and IGF-1 supplementation in OEI vs. OC. This activation 
of protein synthesis pathway was along with a remarkable reduction in the protein content of 
MuRF-1.  
In agreement with our results, Guo et al. [66], reported that testosterone injection plus low 
intensity physical exercise training (T/PT) or vehicle plus physical training (V/PT) for 2 
months increased mRNA expression of IGF-1 and FGF21, while reduced mRNA expression 
of MURF1 and MAFbx in skeletal muscle (triceps) in old mice [66]. It is well known that in 
addition to stimulating protein synthesis and hypertrophy, IGF-1 also inhibits protein 
breakdown [62]. The exact mechanism by which increased IGF-1 levels lead to a reduction in 
the level of MuRF1 is currently unclear. However, it was shown that binding of IGF-1 to its 
receptor induces a conformational change in the IGF-1 receptor tyrosine kinase, resulting in a 
multiple auto-phosphorylation cascade. As a consequence, PI3K is activated resulting in Akt 
phosphorylation. Activation of PI3K/Akt, in turn inhibits FOXOs activity. Consequently, 
Inhibition of translocation of FOXOs into the cell nucleus then suppress transcription of the 
atrogin-1 and MuRF1 [97]. Interestingly, we found that protein expression of follistatin and 
total mTOR corresponded with a significant reduction in MuRF1 protein amount in OEI vs. 
OC. In this regard, it is suggested that in addition to the AKT/FOXO-1 pathway, mTOR also 
blocks MuRF-1 and MAF box transcription [62]. This inhibitory effect of mTOR can be 
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mediated by follistatin while these effects were attenuated by the inhibition of mTOR or the 
deletion of S6K1/2. Furthermore, Smad3 is an important intracellular regulator that is able to 
mediate the effects of follistatin on mTOR signaling. In fact, Smad3 can prevent skeletal 
muscle growth through suppression follistatin downstream signaling. Interestingly, follistatin 
can regulate Smad3- and mTOR activity independent of myostatin [170]. Other mechanisms 
that mediate the process of apoptosis is by IKK, which phosphorylates IRS-1 on serine 307 to 
reduce IGF-1 stimulated signaling [62]. NF-кB transcription factors are expressed in skeletal 
muscle and are activated by inflammatory cytokines, particularly TNF-α. The increase in the 
TNF-α level induces activation of an IKKß complex that phosphorylates IкB, resulting in its 
ubiquitination and proteasomal degradation [72]. It has been demonstrated that IKK deletion 
is associated with increased activity of AKT and P70S6K, along with increased protection 
against atrophy. Cytokines activate NF-кB signaling which can directly attenuate IGF-1 
stimulated protein synthesis; this NF-кB activation enhances muscle atrophy and upregulates 
MuRF-1 [62]. In this regard, we observed that two weeks of IGF-1 administration combined 
with 6 weeks endurance training markedly decreased TNF-α and MuRF-1 protein contents 
and elevated IGF-1 levels in OEI compared with OC.  
The most remarkable result to emerge from our data is that protein expression of Bcl-2 was 
significantly higher in OEI than in OC and OE. Furthermore, Bax to Bcl-2 ratio as an 
apoptotic index was significantly lower in OEI vs. OC.  
Alterations of the mitochondrial Bcl-2 family pathway may be a potential mechanism leading 
to apoptosis in aging skeletal muscle [98]. The Bcl-2 gene family regulates the apoptotic 
process through the balance of pro-apoptotic (Bax, Bcl-XS) and anti-apoptotic products (Bcl-
2, Bcl-XL) [251]. The ratio of pro- to anti-apoptotic proteins (e.g., Bax/Bcl-2) regulates 
myonuclei and cell survival by controlling mitochondrial membrane stability. Decreased 
mitochondrial membrane stability and increased pore formation initiate the release of Cyto C, 
formation of the apoptosome, catalyzed by Apaf-1 (apoptotic protease activating factor-1), 
and followed by the cleavage and activation of caspase-9 and caspase-3 [98]. The mechanism 
by which IGF-1 protects cells from apoptosis is not yet completely understood. However, it 
has been argued that IGF-1 increased the phosphorylation of the pro-apoptotic factor Bad and 
the levels of the anti-apoptotic protein Bcl-2 [252]. In fact, interaction of the IGF-1R with 
IRS-1 activates PI3-ki, which in turn activates Akt/ PKB. The concluding step is the 
phosphorylation, by Akt/PKB, of BAD, one of the members of the Bcl-2 family of proteins 
[253]. 
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Our result also demonstrated that protein contents of SIRT3 and Nrf2, but not SIRT1, PGC-
1a, Cyto C and Cox 4, were significantly increased in OEI compared with OC.  
Indeed critical roles of SIRT3 and Nrf2 in mitochondrial biogenesis have been described 
[254] and both of them play an important role in antioxidant response element signaling 
pathway [255, 256]. As mentioned before, elevated levels of SIRT3 and Nrf2 proteins could 
be the result, at least in part, of adaptive responses to endurance training. However, IGF 
pathways can also contribute to mitochondria biogenesis and function. In this respect, Guo et 
al. [66] reported that increased mRNA expression of IGF1 and FGF21 following 2 months of 
testosterone injection combined with low intensity physical exercise training led to increased 
mitochondrial DNA copy number and expression of markers for mitochondrial biogenesis 
[66]. In support of this notion, it has been shown just recently that suppression of IGF-1 and 
mTOR contributes to impairments in mitochondrial biogenesis and function in aging G3 
mTerc-/- mice (telomerase RNA component knockout) [257].  
In summary, our findings demonstrated that 6 weeks endurance training combined with 2 
weeks IGF-1 administration positively affected some cellular markers involved in sarcopenia 
via increased IGF-1 levels and activation of its downstream pathways. 
 
 
 
 
 
 
 
 
 
 
 
 
94 
 
6. Conclusions 
 
In conclusion, our findings demonstrate that aging is associated with activation of signaling 
pathways involved in sarcopenia. Based on our study, it seems that among cellular factors 
that are responsible for protein synthesis and degradation, increased activity of proteolysis 
signaling, such as FOXO and apoptosis are contributed more to the onset and progression of 
sarcopenia than decreased anabolic pathways.  
In regard to our finding, short term ET may attenuate sarcopenic conditions in old rats. This 
protective effect of ET seems to be due to, at least in part, improvement of mitochondria 
biogenesis and function as well as reduced levels of factors involved in protein degradation, 
such as MuRF1, in aged skeletal muscle.  
According to the results of this study, combination of ET and IGF-1 administration can 
enhance the effects of ET alone on sarcopenic rats. This reinforcing effect of IGF-1 is likely 
to be through the modulation of activator and inhibitor factors of apoptosis such as TNF-α 
and   Bcl-2, respectively. 
However, in order to achieve the best combination therapy it is essential for future researches 
to examine the impact of the intensity and duration of ET, as well as that of different doses of 
the hormone at various level of sarcopenia in both old female and male subjects. 
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7. Summary of thesis 
 
7.1 Summary in English 
 
Introduction: The aging process is associated with reduced physiological and functional of 
several body systems. Loss of muscle mass with aging, also known as sarcopenia, is 
associated with elevated risk of cardiac, pulmonary, and metabolic disease processes, which 
further contributes to the socioeconomic burden. It has been well documented that IGF-1 and 
mitochondria signaling pathways play important roles in protein synthesis and degradation in 
skeletal muscle of mammalian. In this regard, we hypothesized that endurance training and   
IGF-1 treatment can positively affect cellular markers involved in sarcopeni. Methodology: 
Fifteen young (3 months old) and 15 old (26 months old) male Wistar rats were were 
assigned to one of the following groups: young control (YC), young exercised (YE), young 
exercised and IGF-1-treated (YEI), old control (OC), old exercised (OE), and old exercised 
and IGF-1-treated (OEI). Exercised rats were introduced to treadmill running for 3 days; then 
for the next 2 weeks the running speed was set at 10 m/min, with a 5% incline for 30 
min/day, 5 days per weeks. The running speed and duration of the exercise were gradually 
increased to 60% of VO2 max of the animals. In order to protein measurement, frozen vastus 
lateralis samples were weighed and homogenized and western blot were used. Data were 
analyzed by SPSS program version 21 and significance level was set at p < 0.05. Result: Our 
result demonstrated that aging was associated with a reduced level of anabolic factors 
including IGF-1 plasma levels and expression level of follistatin and an increased in catabolic 
agents including Myostatin in old rat. The data from our study showed that 6 weeks 
endurance exercise training significantly increased the amount of follistatin and mitochondria 
function such as Cyto C, Cox 4 and Nrf2 and also decreased levels of catabolic factors 
including MuRF 1 and 2. Our findings demonstrated that 6 weeks endurance training 
combined with 2 weeks IGF-1 administration positively affected some cellular markers 
involved in sarcopenia via increased IGF-1 levels and activation of its downstream pathways.  
Discussion and conclusion: According to the results of this study, combination of ET and 
IGF-1 administration can enhance the effects of ET alone on sarcopenic rats. This reinforcing 
effect of IGF-1 is likely to be through the modulation of activator and inhibitor factors of 
apoptosis such as TNF-α and   Bcl-2, respectively. 
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7.2 Summary in Hungarian (Összefoglalás) 
 
Bevezetés: az öregedés folyamata során számos fiziológiai és funkcionális változás 
következik be az élő szervezetekben. Az idősödő szervezet vázizom vesztése, más néven 
szarkopénia, pulmonáris- kardiológia és nem utolsó sorban metabolikus elváltozásokkal 
hozható összefüggésbe. Ezek betegségek igen jelentős szocioökonómiai terhet jelentenek 
társadalmunk számára. Egy ideje jól dokumentált tény, hogy emlős szervezetek 
vázizomzatában az IGF-1 és a mitokondriális jelátviteli útvonalak egyaránt fontos szerepet 
játszanak a fehérjék szintézisben és lebontásban. Ennek fényében feltételeztük, hogy az 
állóképességi edzés és az IGF-1 kezelés pozitív hatást fog kifejteni a szarkopéniával 
összefüggésbe hozható sejtmarkerek szintjére.  
Anyag és módszer: vizsgálatunk során fiatal (3 hónapos, n=15) és idős (26 hónapos, n=15) 
wistar patkányokkal dolgozunk. Mind az idős, mind a fiatal populációból 3 csoportot 
képeztünk: Fiatal kontrol (YC), fiatal edző (YE), fiatal edző és IGF-1 kezelt (YEI), továbbá 
idős kontrol (OC), idős edző (OE), idős edző IGF-1 kezelt (OEI). Az állatok edzését 
futópadon végeztük: a háromnapos szoktatási időszak után az álatok 2 hétig 10m/min 
sebességgel 5% emelkedő mellet edzettek 30pecgig heti öt napon. Ezt követően a terhelés 
fokozatosan a maximális relatív oxigén felvételük 60%-hoz lett igazítva. Az IGF-1 kezelést a 
vizsgálat utolsó két hetében alkalmaztuk. A kombinált csoport egyedei naponta ~5μg/kg 
mennyiségű IGF-1 et kaptak 0.5 μL/hr emissziós rátával, a kontrol csoportnak placebóként 
fiziológiás sóoldatot adagoltunk. A fehérje összetétel maghatározást Western Blott analízissel 
végeztük. A vizsgálati állatok vastus laterális izmait folyékony nitrogénnel fagyasztottuk, 
majd tömegmérés után homogenizáltuk. A csoportok közti különbség meghatározásánál 
SPSS (vol.21) programot használtunk, a szignifikancia szintet p < 0,05 értékben határoztuk 
meg.  
Eredmények: méréseink során demonstráltuk, hogy az öregedés során csökkenek az 
anabolikus folyamatok indikátorai, ezek közül kiemelten a plazma IGF-1 mennyiség és a 
follisztatin expresszió. A katabolikus markerek tekintetében a myosztatin mennyiség 
növekedett az idős patkányokban. Eredményeink szerint 6 hetes állóképességi edzés 
szignifikánsan képes növelni a follisztatin mennyiséget és fokozza a mitokondriális 
funkciókat, melyeket Cyto C, Cox4 és Nrf-2 fehérjék emelkedése szemléltet. Mind e mellet 
MuRF-1 és MuRF-2 katabolikus faktor csökkenés is tapasztalható a kezelés hatására. A 
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kombinált kezelés számos esetben pozitívan befolyásolta a szarkopénia markerek szintjét, 
feltehetően az IGF-1 jelátviteli útvonal aktiválódásán keresztül.  
Diszkusszió, összefoglalás: Eredményeink alapján, az állóképességi edzés és az IGF-1 
szuplementáció együttalkalmazása tovább tudja fokozni az testmozgás jótékony hatását 
szarkopéniás patkányok esetében. A tapasztalt szinergikus hatás úgy tűnik az apoptózist gátló 
és aktiváló folyamtok modulációjában rejlik, kiemelve a TNF-alfa és a Bcl-2 fehérjék által 
vezérelt útvonalakat. 
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